Compositions and methods for targeted thermomodulation
Abstract
A composition comprising a cosmetically acceptable carrier and a plurality of plasmonic nanoparticles in an amount of from 109 to 1018 nanoparticles per milliliter of composition, for use in a method of treating acne in a mammalian subject, wherein the plasmonic nanoparticles are selected from nanorods , nanoshells, nanospheres, nanoplates or nanorices that are encapsulated within a matrix formed of a matrix component selected from silica or polyethylene glycol, wherein said method comprises i) topically administering said composition to a skin surface of the subject; ii) providing means of penetration to redistribute the plasmonic nanoparticles from the skin surface to a sebaceous gland; iii) washing the plasmonic nanoparticles from the skin surface; iv) causing irradiation of the skin surface by light, and v) detaching the plasmonic nanoparticles from the sebaceous gland.

Term
4.9 yearsto projected expiry
Projected expiry 26 August 2031, counted from filing; an application has no term until it is granted.
- Priority
- Filed
- Published
- Today
- Projected expiry
25 claims: 2 independent, 23 dependent
- 1REIVINDICACIONES 1. Una composición que comprende un portador cosméticamente aceptable y una pluralidad de nanopartículas plasmónicas en una cantidad de 109 a 1018 nanopartículas por mililitro de composición, para uso en un método para tratar el acné en un sujeto mamífero, en donde las nanopartículas plasmónicas se seleccionan de nanobarras, nanocorazas, nanoesferas, nanoplacas o nanoarroces que se encapsulan dentro de una matriz formada de un componente de la matriz seleccionado de sílice o polietilenglicol, en donde dicho método comprende i) administrar tópicamente dicha composición a una superficie de la piel del sujeto;ii) proporcionar medios de penetración para redistribuir las nanopartículas plasmónicas desde la superficie de la piel a una glándula sebácea;iii) lavar las nanopartículas plasmónicas de la superficie de la piel;iv) provocar la irradiación de la superficie de la piel mediante luz, y v) desprender las nanopartículas plasmónicas de la glándula sebácea.
- 2Un método para eliminar el pelo de un sujeto mamífero, que comprende las etapas de i) administrar por vía tópica a una superficie de la piel del sujeto una composición que comprende un portador cosméticamente aceptable y una pluralidad de nanopartículas plasmónicas en una cantidad de 109 a 1018 nanopartículas por mililitro de la composición, en donde las nanopartículas plasmónicas se seleccionan de nanobarras, nanocorazas, nanoesferas, nanoplacas o nanoarroces que se encapsulan dentro de una matriz formada de un componente de la matriz seleccionado de sílice o polietilenglicol;ii) proporcionar medios de penetración para redistribuir las nanopartículas plasmónicas desde la superficie de la piel a un folículo piloso;iii) lavar las nanopartículas plasmónicas de la superficie de la piel;iv) provocar la irradiación de la superficie de la piel mediante luz, y v) desprender las nanopartículas plasmónicas del folículo piloso junto con el folículo piloso dañado.
- 3La composición para uso de acuerdo con la reivindicación 1 o el método de la reivindicación 2, en donde las nanopartículas comprenden plata u oro.
- 4La composición para uso o el método de la reivindicación 3, en donde el componente de matriz es sílice.
- 5La composición para uso o el método de la reivindicación 3, en donde el componente de la matriz es polietilenglicol.
- 6La composición para uso o el método de la reivindicación 3, en donde las nanopartículas son compuestos metálicos de plata y sílice.
- 7La composición para uso o el método de la reivindicación 3, en donde las nanopartículas son nanoesferas de oro recubiertas con polietilenglicol.
- 8La composición para uso de acuerdo con la reivindicación 1 o el método de la reivindicación 2, en donde la fuente de luz comprende excitación de mercurio, xenón, deuterio o un haluro metálico, fosforescencia, incandescencia, luminiscencia, diodo emisor de luz o luz solar.
- 9La composición para uso de acuerdo con la reivindicación 1 o el método de la reivindicación 2, en la que los medios de penetración comprenden ultrasonido de alta frecuencia, ultrasonido de baja frecuencia, masaje, iontoforesis, flujo de aire a alta presión, flujo de líquido a alta presión, vacío, tratamiento previo con fototermólisis fraccionada o dermoabrasión, o una combinación de los mismos.
- 10La composición para uso de acuerdo con la reivindicación 1 o el método de la reivindicación 2, en donde la irradiación comprende luz que tiene una longitud de onda de luz entre aproximadamente 200 nm y aproximadamente 10.000 nm, una fluencia de aproximadamente 1 hasta aproximadamente 100 julios/cm2, un ancho de pulso de aproximadamente 1 femtosegundo hasta aproximadamente 1 segundo, y una frecuencia de repetición de aproximadamente 1 Hz hasta aproximadamente 1 THz.1
- 11La composición para uso de acuerdo con la reivindicación 1 o el método de la reivindicación 2, en donde el portador cosméticamente aceptable comprende un aditivo, un colorante, un emulsionante, una fragancia, un humectante, un monómero polimerizable, un estabilizador, un disolvente o un surfactante.
- 12La composición para uso de la reivindicación 7 o el método de la reivindicación 7, en donde el surfactante se selecciona del grupo que consiste en:lauret 2-sulfato de sodio, dodecil sulfato de sodio, lauril sulfato de amonio, octech-1/deceth-1 sulfate de sodio, lípidos, proteínas, péptidos o derivados de los mismos.
- 13La composición para uso de la reivindicación 7 o el método de la reivindicación 7, en donde el portador cosméticamente aceptable comprende surfactante en una cantidad entre aproximadamente 0,1 y aproximadamente 10,0% peso a peso del portador.
- 14La composición para uso de la reivindicación 7 o el método de la reivindicación 7, en donde el disolvente se selecciona del grupo que consiste en agua, propilenglicol, alcohol, hidrocarburo, cloroformo, ácido, base, acetona, éter dietílico, sulfóxido de dimetilo, dimetilformamida, acetonitrilo, tetrahidrofurano, diclorometano y acetato de etilo.
- 15La composición para uso de acuerdo con la reivindicación 1 o el método de la reivindicación 2, en donde las nanopartículas plasmónicas tienen un tamaño de partícula en el intervalo de aproximadamente 1 nm hasta aproximadamente 1.000 nm.
- 16La composición para uso de acuerdo con la reivindicación 1 o el método de la reivindicación 2, en donde las nanopartículas plasmónicas tienen una densidad óptica de al menos aproximadamente una DO 1 a una o más longitudes de onda de resonancia pico.
- 17La composición para uso de acuerdo con la reivindicación 1 o el método de la reivindicación 2, en donde las nanopartículas plasmónicas tienen una densidad óptica de DO 10-DO 1.000 a una o una pluralidad de longitudes de onda de resonancia pico.
- 18La composición para uso de acuerdo con la reivindicación 1 o el método de la reivindicación 2, en donde la luz tiene una longitud de onda seleccionada del grupo que consiste en:755 nm, 800-810 nm y 1.064 nm.
- 19La composición para el uso de acuerdo con la reivindicación 1 o el método de la reivindicación 2, en donde dicho método comprende además tratar previamente la superficie de la piel para aumentar el suministro de las nanopartículas plasmónicas desde la superficie de la piel al componente del tejido dérmico, en donde el tratamiento previo comprende por lo menos uno del grupo que consiste en la depilación a través de afeitado, encerado, exfoliación de la superficie con cianoacrilato, tratamiento con tioglicolato de calcio u otras técnicas para eliminar el vástago del pelo y/o los tapones del folículo piloso y la exfoliación.
- 20La composición para uso de acuerdo con la reivindicación 1 o el método de la reivindicación 2, en donde las nanopartículas plasmónicas comprenden plata, oro, níquel, cobre, titanio, silicio, galadio, paladio, platino o cromo.
- 21La composición para el uso de acuerdo con la reivindicación 1 o el método de la reivindicación 2, en donde dicha pluralidad de nanopartículas plasmónicas está presente en una cantidad de 1011 a 1013 nanopartículas por mililitro de la composición.
- 22La composición para su uso de acuerdo con la reivindicación 1, en donde las nanopartículas plasmónicas son nanoplacas de plata, en donde la nanoplca tiene una dimensión en un rango de 100-250 nm, en donde el recubrimiento es un recubrimiento hidrofílico de sílice, en donde dicha pluralidad de nanopartículas plasmónicas está presente en una cantidad de 1011 a 1013 nanopartículas por mililitro de la composición, en donde las nanopartículas plasmónicas están desensambladas, en donde las nanopartículas plasmónicas no ensambladas no están unidas entre sí a través de una fuerza física o un enlace químico ya sea directa o indirectamente a través de un intermediario, en donde la irradiación comprende luz que tiene una longitud de onda de luz seleccionada del grupo que consiste en:755 nm, 800-810 nm y 1064 nm.
- 23La composición para su uso de acuerdo con la reivindicación 1, en donde las nanopartículas plasmónicas comprenden oro, en donde el recubrimiento es un recubrimiento hidrofílico de polietilenglicol, en donde dicha pluralidad de nanopartículas plasmónicas está presente en una cantidad de 1011 a 1013 nanopartículas por mililitro de la composición, en donde las nanopartículas plasmónicas no están ensambladas, en donde las nanopartículas plasmónicas no ensambladas no están unidas entre sí mediante una fuerza física o un enlace químico directa o indirectamente a través de un intermediario, en donde la irradiación comprende luz que tiene una longitud de onda de luz seleccionada del grupo que consiste en:755 nm, 800-810 nm y 1064 nm.
- 24El método de la reivindicación 2, en donde las nanopartículas plasmónicas son nanoplacas de plata, en donde la nanoplaca tiene una dimensión en un rango de 100-250 nm, en donde el recubrimiento es un recubrimiento hidrofílico de sílice, en donde dicha pluralidad de nanopartículas plasmónicas está presente en una cantidad de 1011 a 1013 nanopartículas por mililitro de la composición, en donde las nanopartículas plasmónicas no están ensambladas, en donde las nanopartículas plasmónicas no ensambladas no están unidas entre sí mediante una fuerza física o un enlace químico directa o indirectamente a través de un intermediario, en donde la irradiación comprende luz que tiene una longitud de onda de luz seleccionada del grupo que consiste en:755 nm, 800-810 nm y 1064 nm.
- 25El método de la reivindicación 2, en donde las nanopartículas plasmónicas comprenden oro, en donde el recubrimiento es un recubrimiento hidrofílico de polietilenglicol, en donde dicha pluralidad de nanopartículas plasmónicas está presente en una cantidad de 1011 a 1013 nanopartículas por mililitro de la composición, en donde las nanopartículas plasmónicas no están ensambladas, en donde las nanopartículas plasmónicas no ensambladas no están unidas entre sí mediante una fuerza física o un enlace químico directa o indirectamente a través de un intermediario, en donde la irradiación comprende luz que tiene una longitud de onda de luz seleccionada del grupo que consiste en:755 nm, 800-810 nm y 1064 nm.
Independent claims25
160 paragraphs in 1 section, as filed
DESCRIPTION
Compositions and methods for directed thermomodulation
Cross reference
Field of the Invention
The field of the invention is nanoparticles for use in cosmetic, diagnostic and / or therapeutic procedures. Background of the invention
Laser skin treatments are widely known and have been highly promoted for therapeutic and cosmetic use. Therapeutically, potential uses for laser skin therapy include laser ablation of cancer cells in cancer patients and laser ablation of damaged tissue in burn victims. Cosmetic applications for laser skin therapy are much more numerous and include hair removal / reduction, treatment of dyschromia, shrinkage of the skin after operations such as liposuction, acne treatment, chemical abrasion or physical unwanted marks on the skin, surgical treatments that include reduction of the nose and facial and neck lifts, and other aesthetic purposes for skin reshaping. See for example documents US 2005/203495 A1, WO 2009/124189 A1 and W<sup>or </sup>2006/051542 A1 as an example of the prior art dealing with methods that involve plasmonic particles.
Summary of the invention
Despite the promise of laser therapy for therapeutic and cosmetic products for the skin, current laser procedures are limited in effectiveness, requiring a prohibitive number of repeated treatments and increased costs. Non-optimal laser treatments also have limited specificity, resulting in debilitating clinical side effects, such as nonspecific skin damage, skin irritation and scarring.
Light-based hair removal systems suffer from particularly low rates of effectiveness in removing light hair (hair, blond, gray, redhead). Multiple treatments (even 6 or more) are insufficient to achieve a therapeutic result in patients with blond-gray or red-haired hair, even with the use of topically applied chromophores such as carbon. In addition to light hair removal, thermoablation technology has untapped potential in the fields of wound healing, tissue remodeling, vascular repair and acne treatment.
Acne vulgaris is the result of obstruction of the pilosebaceous unit, which consists of the capillary stem, the hair follicle, the sebaceous gland and the capillary erector muscle, which leads to the accumulation of sebum produced from the sebaceous gland and the subsequent colonization of bacteria inside the follicle. Microcomedones are formed as a result of accumulated sebum progress to non-inflamed skin spots (white / pimples), or even skin imperfections that recruit inflammatory cells and lead to the formation of papules, nodules and cysts filled with pus. The consequences of untreated acne vulgaris often include hyperpigmentation, scarring and disfiguration, as well as significant psychological distress. Therefore, acne treatments seek extensively to reduce the accumulation of sebum and microorganisms within the follicles and sebaceous gland.
The methods that involve light and laser are promising for the treatment of skin disorders, but they are still insufficiently effective. Ultraviolet (UV) / blue light is approved by the FDA for the treatment of mild to moderate acne only, due to its anti-inflammatory effects mediated in skin cells (keratinocytes), potentially through the action of endogenous porphyrin photosensitizers within of the follicles. Exogenous porphyrin precursors such as 5-aminoluveulinic acid (5-ALA) have been formulated for topical or oral administration and are shown to accumulate inside sebaceous follicles, absorb photons by exposure to red light and form species oxygen reagents that directly damage cell membranes and proteins. This procedure that combines application of porphyrin and high intensity red light, called "photodynamic therapy", has been shown to reduce the production of sebum and acne by 50% for 20 weeks after irradiation. However, high intensity energies (50-150 J / cm2) are required to damage the skin structures of the sebaceous glands, and transdermal penetration of porphyrin leads to unwanted side effects that include sensitivity to light, pain, inflammation, hyper / hypopigmentation and permanent scars.
In order for laser therapy to reach its full utility in the treatment of human skin disorders, methods must be achieved to locally induce photodestruction in skin structures without affecting the surrounding tissues.
New compositions and methods useful in the directed thermomodulation of target cell populations and target tissues are provided herein for certain treatment purposes. cosmetics and the treatment and prevention of diseases and chronic and acute disorders.
In one aspect, compositions of matter are described herein. For example, in one embodiment a composition is provided comprising a cosmetically acceptable carrier and a plurality of plasmonic nanoparticles in an amount effective to induce thermomodulation in a region of target tissue with which the composition is contacted topically.
In some embodiments, the composition comprises plasmonic nanoparticles that are activated by exposure to the energy supplied from a non-linear excitation surface plasmon resonance source to the region of target tissue. In subsequent or additional embodiments, compositions herein comprising at least one plasmonic nanoparticle comprising a metal, a metal compound, a metal oxide, a metal salt, an electrical conductor, an electrical superconductor, an electrical semiconductor, a description are described herein. dielectric, a quantum dot or a compound from a combination thereof. In subsequent or additional embodiments, a composition is described herein in which a substantial amount of the plasmonic particles present in the composition comprise nanostructures with geometric fit. In subsequent or additional embodiments, a composition is described herein in which the plasmonic particles comprise any currently known geometric shape or that is believed to absorb light and generate plasmon resonance at a desired wavelength, including nanoplates, solid nanochromes. , hollow nanowires, nanobars, nanoarroces, nanospheres, nanofibers, nanowires, nanopyramids, nanoprisms, nanostars or a combination thereof. In still further embodiments, a composition is described herein where the plasmonic particles comprise silver, gold, nickel, copper, titanium, silicon, gallium, palladium, platinum or chromium.
In some embodiments, a composition is provided herein comprising a cosmetically acceptable carrier comprising an additive, a colorant, an emulsifier, a fragrance, a humectant, a polymerizable monomer, a stabilizer, a solvent or a surfactant. In one embodiment, a composition is provided herein in which the surfactant is selected from the group consisting of: sodium lauret 2-sulfate, sodium dodecyl sulfate, ammonium lauryl sulfate, octech-1 / deceth-1 sodium sulfate, lipids, proteins, peptides or derivatives thereof. In one embodiment, a composition is provided in which a surfactant is present in an amount between about 0.1 and about 10.0% weight to weight of the carrier. In yet another embodiment, the solvent is selected from the group consisting of water, propylene glycol, alcohol, hydrocarbon, chloroform, acid, base, acetone, diethyl ether, dimethylsulfoxide, dimethylformamide, acetonitrile, tetrahydrofuran, dichloromethane and ethyl acetate. In one embodiment, the composition comprises plasmonic particles having an optical density of at least about OD 1 at one or more peak resonance wavelengths.
In further or further embodiments, a composition is described herein where plasmonic particles comprise a hydrophilic or aliphatic coating, in which the coating is not substantially adsorbed on the skin of a mammalian subject, and in which the coating comprises polyethylene glycol, silica, silica oxide, polyvinylpyrrolidone, polystyrene, a protein or a peptide. In even a further embodiment, thermomodulation comprises damage, ablation, lysis, denaturation, deactivation, activation, induction of inflammation, activation of heat shock proteins, disruption of cell signaling or alteration of the cell microenvironment in the region of target tissue. Moreover, in certain presentations, the target tissue region comprises a sebaceous gland, a component of a sebaceous gland, a sebum, a component of a sebum, sebum or a hair follicle infundibulum. In other embodiments, the region of target tissue comprises a bulge, a bulb, a stem cell, a niche of stem cells, a dermal papilla, a cortex, a cuticle, a hair sheath, a medulla, an erector muscle of the hair, a layer of Huxley or a layer of Henle.
In another aspect, methods for conducting directed tissue ablation are described herein. For example, in one embodiment, there is provided a method to perform a directed ablation of a tissue to treat a mammalian subject in need, comprising the steps of i) topically administering to a surface of the subject's skin the composition of the claim 1; ii) provide penetration means to redistribute plasmonic particles from the skin surface to a component of the dermal tissue; and iii) cause irradiation of the skin surface by light. In other embodiments or additional embodiments, a method is provided in which the light source comprises excitation of mercury, xenon, deuterium or a metal halide, phosphorescence, incandescence, luminescence, light emitting diode or sunlight. In other embodiments or additional embodiments, a method is provided in which the penetration means comprise high frequency ultrasound, low frequency ultrasound, massage, iontophoresis, high pressure air flow, high pressure liquid flow, vacuum, treatment prior with fractional photothermolysis or dermabrasion, or a combination thereof. In other further embodiments, a method is provided in which the irradiation comprises light having a wavelength of light between about 200 nm and about 10,000 nm, a creep of about 1 to about 100 joules / cm2, a pulse width of about 1 second to about 1 second, and a repetition frequency of about 1 Hz to about 1 THz.
In a further aspect, a composition is provided herein comprising a cosmetically acceptable carrier, an effective amount of sodium dodecyl sulfate and a plurality of plasmonic nanoparticles in an amount effective to induce thermal damage in a region of target tissue with which the composition is puts on topically contact, wherein the nanoparticles have an optical density of at least about OD 1 at a resonance wavelength of about 810 nanometers or 1,064 nanometers, where the plasmonic particles comprise a silica coating of about 5 to about 35 nanometers, wherein the carrier Acceptable includes water and propylene glycol.
A system for hair laser ablation or acne treatment is provided comprising a composition and a plasmonic energy source suitable for application to human skin, either as a composition for use in a method to treat acne or a method for removing hair, but strictly limited to the definition as set forth in the appended claims.
Brief description of the figures
Figure 1 is illustrative of schemes representing certain embodiments of the use of formulations for hair removal and acne treatment. It is represented (A) for hair removal, the plasmonic formulation of nanoparticles (black) that is 1. applied topically to human skin, 2. introduced deeply into the follicle and washed from the surface of the skin, 3. irradiated with a clinical laser at a resonant wavelength at the maximum absorption wavelength of the plasmonic particle, and 4. detach from the follicle along with the damaged hair follicle; and (B) for the treatment of acne, the plasmonic formulation of nanoparticles (black) that is 1. applied topically to human skin, 2. supplied specifically to the sebaceous gland and washed from the surface of the skin, 3. irradiated with a clinical laser at a resonant wavelength at the maximum absorption wavelength of the plasmonic particle, and 4. detach from the target site where the accumulated sebum and sebum production capacity of the sebaceous gland are destroyed.
Figure 2 is illustrative of a temperature profile of certain embodiments of the plasmonic nanoparticle formulations (SL-001, triangles) provided herein compared to examples of current clinical dyes, carbon lotion (circles), aerosol spray. meladin (diamonds) and indocyanine green (squares), after exposure to 1,064 nm, 20 J / cm2, 55 ms laser pulses. SL-001 and the dyes were also diluted 1: 1,000 from the clinical concentration (SL-001 1,000 OD, carbon 20-200 mg / ml, meladin 1 mg / ml, ICG 5 mg / ml) .n = 3, standard error of the mean.
Figure 3 is illustrative of the penetration of the hair follicle of fluorescently labeled nanoparticles, which are determined using porcine skin explants and confocal imaging of certain embodiments of the object described herein. A diagram of the treated, sectioned and swine swine skin is depicted (at an angle to the follicle, in two serial planes of 60 pm: 'plane 1' (showing the follicular infundibulum) and 'plane 2' (showing the deep follicle); (B) representative confocal images show red fluorescent nanoparticles (548 nm) within the superficial and deep follicle, but not in the underlying dermis; and (C) red fluorescent nanoparticles retained in the deep follicle (~ 400 pm) with large magnification. Green is the autofluorescence of tissue.
Figure 4 is illustrative of a hair follicle penetration of plasmonic nanoparticles determined using porcine skin explants and dark field imaging. It shows (A) a scheme of the treated swine skin, sectioned and forming a horizontal image with the follicle; (B) Bright blue plasmonic particles are visible in a section of 1.2 mm deep, and differ from (C) untreated pig skin (negative control), where there are no visible pigments.
Figure 5 represents the clinical observations on live human skin treated with laser only (left forearm) or laser plasmonic particles (right forearm), demonstrating non-specific and specific photothermal damage. (A, B) In the upper panel, human skin was irradiated with laser pulses of 810 nm (30 J / cm2, 30 ms, 2 passes) alone (A), or after treatment with a resonant formulation at 830 nm, Plasmonic nanoparticles not coated in 20% propylene glycol (B). The plasmonic nanoparticle formulation was applied with a 3-minute massage, and the skin surface was cleaned with 3 applications of water and ethanol alternately before laser irradiation. At 30 minutes after laser irradiation, non-specific clinical burns were observed in B compared to A, due to significant photothermal heating of the residual, uncoated particles on the skin surface. (C, D) In the lower panel, human skin was irradiated with laser pulses of 1,064 nm (40 J / cm2, 55 ms, 3 passes) alone (C), or after treatment with a resonant formulation at 1,020 nm, Plasma nanoparticles coated with silica in 20% propylene glycol (D). The plasmonic nanoparticle formulation was applied with a 3-minute massage, and the skin surface was cleaned with 3 applications of water and ethanol alternately before laser irradiation. Within 30 minutes after laser irradiation, no evidence of skin burn or erythema was observed in D or C, since silica-coated particles could be sufficiently cleansed from the skin's surface. The enlarged photograph of D showed a specific photothermal damage (peripheral erythema and edema) at the target site of the nanoparticles.
Figure 6 is a photograph showing specific photothermal damage of nanoparticles in living human skin treated with a formulation of plasmonic nanoparticles and clinical laser. A formulation of resonant plasmonic nanoparticles at 1020 nm, coated with silica (200 nm in diameter) in 20% propylene glycol and a 3 minute massage with live human skin, was contacted. The procedure was repeated 3 times and the surface of the the skin with 3 applications of water and ethanol alternately to remove residual particles. The treated skin was irradiated with 1.064 nm laser pulses (40 J / cm2, 55 ms, 3 passes). After laser irradiation, clinical observation of peripheral erythema and edema were visible in the hair follicles where the nanoparticles were directed, but were not visible in the surrounding tissue or not treated with particles.
Figure 7 is illustrative of the administration of a plasmonic nanoparticle formulation to a sebaceous gland of human skin. (A) Confocal microscopic image of a biopsy and section of human skin, immunostained for the basement membrane of collagen IV (blue) and marker of the PGP 9.5 nerve (green), shows the microanatomy of the hair follicle (HF) and the sebaceous gland (SG). The red is made of silica nanoparticles (200 nm). (B) Schematic and dark-field microscope image of excised human skin treated with a plasmonic nanoparticle formulation, then sectioned and forming a horizontal image with the follicle. The bright blue plasmonic particles are visible up to 400 pm deep and inside the human sebaceous gland.
Figure 8 is illustrative of cosmetic formulations of plasmonic nanoparticles for the selection of sebaceous glands that include surfactants. Silica coated nanoparticles (200 nm in diameter, OD 100) were formulated in 20% propylene glycol with the addition of sodium dodecyl sulfate (SDS) or sodium lauret 2-sulfate (SLES) surfactants, applied to human skin with massage ultrasound and the skin was sectioned in horizontal planes for dark field microscopy. (A) Plasma particle formulations in 1% SDS / 20% Pg penetrated the sebaceous gland up to 400 pm as in Figure 7. (B) Plasma particle formulations in 1% SLES / 20% PG penetrated in the sebaceous gland until 600 pm. The insert shows a section of skin without visible particles (scale bar 40 pm). The sebaceous gland is pseudo-outlined.
Figure 9 is an image that represents the impact of massage against ultrasound on nanoparticles destined for the human follicle and the sebaceous gland. Silica coated nanoparticles (200 nm in diameter, OD 100) were formulated in 1% SDS / 20% propylene glycol and applied to human skin with massage or ultrasound. Darkfield images of horizontal flat sections taken with a low (20x) and high (50x) magnification show (A) little or no accumulation of plasmonic particles in the follicular infundibulum after massage alone, compared to (B) infundibulum expansion Follicular and significant accumulation of plasmonic particles after ultrasound alone.
Figure 10 represents an embodiment of the cosmetic formulations of plasmonic nanoparticles intended for the sebaceous glands. Plasmonic nanoparticles comprising different shapes and coatings were formulated in 1% SDS / 20% propylene glycol and applied to human skin with ultrasound massage, and the skin was sectioned in horizontal planes for dark field microscopy. (A) Nanobars coated with polyethylene glycol (PEG) (gold, dimension 15 x 30 nm) were observed inside the follicular infundibulum up to 200 pm deep (white arrow). (B) Lower concentration (DO 10). Silica-coated nanoplates were observed (silver, 200 nm diameter) up to 600 pm deep in the follicle and in the sebaceous gland (arrow without padding). The box shows sections of skin without visible particles (100 pm scale bar).
Detailed description of the invention
The biology of the physiological and physiopathological growth and remodeling of the tissue and the alterations in cell morphology are more complex than is generally appreciated, involving an interactive network of biological compounds, physical forces and cell types.
An object of the matter described herein is to provide compositions, methods and systems for the non-invasive and minimally invasive treatment of underlying skin and tissues, or other tissue spaces accessible with the use of nanoparticles. Treatment includes, but is not limited to, hair removal, hair growth and regeneration, and skin rejuvenation or resurgence, acne removal or reduction, wrinkle reduction, pore reduction, cellulite ablation and other dermal lipid depositions, removal warts and fungi, thinning or removing scars including hypertrophic scars and keloids, abnormal pigmentation (such as port wine stains), removal of tattoos and skin inconsistencies (for example, in texture, color, tone, elasticity, hydration). Other therapeutic or preventive methods include, but are not limited to, the treatment of hyperhidrosis, anhidrosis, Frey syndrome (gustatory sweating), Horner syndrome and Ross syndrome, actinic keratosis, follicular keratosis, dermatitis, vitiligo, pityriasis , psoriasis, lichen planus, eczema, alopecia, psoriasis, malignant or non-malignant skin tumors.
Unless explained otherwise, all the technical and scientific terms used herein have the same meaning that is commonly understood by one skilled in the art to which this description belongs. Although methods and materials similar or equivalent to those described herein may be used in the practice or test of the present disclosure, suitable methods and materials are described herein. The materials, methods and examples are illustrative only and are not intended to be limiting. Other features of the description are apparent from the following detailed description and the claims.
"Administer" and "administration" as used herein, include providing or provoking the provision of a material to a subject, such as topically, subdermally, subcutaneously, intradermally, enterally, parenteral, rectal, nasal, intravenous, intramuscular, intraperitoneal or other route.
A "suitable carrier for administration" to a subject is any material that is physiologically compatible with a topical route or route of administration to a desired vertebrate subject. The carriers may include solid, dry materials for formulation; or the carrier may include liquid or gel based materials for formulations in liquid or gel forms. The specific type of carrier, as well as the final formulation depends, in part, on the route or selected routes of administration and the type of product.
A "comparable quantity" is an amount that is substantially similar to a given reference or standard.
The "components" of a formulation include any associated product or compound or content within them.
An "effective dose", "effective amount" or "therapeutic amount" is an amount sufficient to cause the desired pharmacological, cosmetic or therapeutic effects, resulting in an effective prevention or treatment of a disease or disorder, or providing a benefit in a vertebrate subject.
A "therapeutic effect" or "therapeutically desirable effect" refers to a change in a domain or region that is being treated in such a way that it exhibits signs that it is carried out in the desired manner, for example, cancer treatment causes destruction. of tumor cells or arrests of tumor cell growth, acne treatment causes a decrease in the number and / or severity of imperfections, Hair removal treatment leads to obvious hair loss, or wrinkle reduction treatment causes wrinkles to disappear.
An "isolated" biological component (such as a nucleic acid, protein or cell molecule) has been substantially separated or purified away from other biological components in which the component was produced, including any other protein, lipids, carbohydrates and other components.
A "nanoparticle", as used herein, generally refers to a particle having at least one of its dimensions from about 0.1 nm to about 9,000 nm.
A "subject" or "patient" as used in the present invention is any vertebrate species.
As used herein, a "substantially pure" or "substantially isolated" compound is substantially free of one or more other compounds.
An "objective tissue" includes a region of an organism in which a physical or chemical force or change is desired. As described herein, examples of target tissues for acne treatment include a sebaceous gland, while examples of target tissues for hair removal include a pilosebaceous unit, a capillary infundibulum, a hair follicle or an epidermis. not follicular A "region" of a target tissue includes one or more tissue components. Examples of target tissue regions include the niche of stem cells, the bump, the sebaceous gland, the dermal papilla, the cortex, the cuticle, the internal root sheath, the external root sheath, the medulla, the layer Huxley, Henle's coat or erector hair muscle. A "domain" of a region of target tissue includes the basement membrane, extracellular matrix, cell surface proteins, unbound proteins / analytes, glyomatrices, glycoproteins or lipid bilayer.
A compound that is "substantially free" of some additional content is totally or almost completely without such content.
A "plasmonic nanoparticle" is a metal structure of nanometric size within which the localized surface plasmons are excited by light. These surface plasmons are surface electromagnetic waves that propagate in a direction parallel to the metal / dielectric interface (for example, metal / air or metal / water).
A "light absorbing nanomaterial" includes a nanomaterial capable of demonstrating a quantum size effect. As described herein, compositions containing plasmonic nanoparticles are provided to induce selective thermodulation in a target tissue.
Plasmonic nanoparticles.
Such compositions contain from about 109 to about 1016 nanoparticles, such as 109, 1010, 1011, 1012, 1013, 1014, 1015, 1016 particles. Preferably, the compositions contain about 1011 to 1013 particles so that the amount of particles located in an effective treatment volume of 1 ml is 109 to 1011. In certain embodiments in which a higher concentration of nanoparticles in a target region is desired, the compositions contain concentrations of particles with optical densities (OD) of 10-1,000, or optical densities greater than 1,000. In some embodiments, these correspond to concentrations of approximately 1-10% w / w or more of nanoparticles.
The nanoparticles can be homogeneous or heterogeneous in size and other characteristics. The nanoparticle size is generally from about 0.1 nm to about 5,000 nm in at least one dimension. Some variation in the size of a population of nanoparticles is expected. For example, the variation may be less than 0.01%, 0.1%, 0.5%, 1%, 5%, 10%, 15%, 25%, 50%, 75%, 100%, 200% or more than 200%. In certain embodiments where optimal plasmonic resonance is desired, a particle size in the range of about 10 nm to about 100 nm is provided. Alternatively, in embodiments where improved penetration of the nanoparticles into a region of target tissue such as a hair follicle is desired, a particle size in the range of about 100 nm to about 1,000 nm is provided. Modulation of the particle size present in the composition is also a useful means of concentrating the composition in an objective domain. In addition, as described herein, nanoparticles having a size range from about 10 nm to about 100 nm can be used as components of a larger molecular structure, generally in the range of about 100 nm to about 1,000 nm. For example, the plasmonic nanoparticle can be surface coated to increase its size, soaked in an acceptable carrier, or it can be entwined or added to other particles, or other materials, that generate a larger particle. In certain embodiments in which at least one dimension of at least one nanoparticle within a solution of plasmonic nanoparticles is below 50-100 nm, the surface of the nanoparticles may be coated with a matrix (eg silica) of 10- 100 nm thick or more in order to increase that dimension or particle to 50-100 nm or more. This larger size can increase the supply of all nanoparticles to a target region (for example, hair follicle) and limit the supply to a non-target region (for example, dermis).
Important considerations when generating nanoparticles include: 1) the zeta potential (positive, negative, or neutral) and charge density of the resulting particles and compositions; 2) the hydrophilicity / hydrophobicity of the particles and the resulting compositions; 3) the presence of an adsorption layer (for example, a particle slip plane); and 4) adhesion properties to the target cells. To the surfaces of the nanoparticles, functional groups with thiolated fractions having negative, positive or neutral charges (for example, carboxylic acid, amine, hydroxyls) in various proportions can be added. In addition, an anion-mediated surface coating (for example, acrylate, citrate and others), a surfactant coating (for example, sodium dodecyl sulfate, sodium lauret 2-sulfate, ammonium lauryl sulfate, octech-1 / deceth-) can be used 1 sodium sulfate, lecithin and other surfactants including cetyl trimethylammonium bromide (CTAB), lipids, peptides), or protein / peptide coatings (e.g., albumin, ovalbumin, egg protein, milk protein, other foods, plants, animals, bacteria, yeasts or recombinantly derived protein). Also useful are block copolymers. In addition, the utility of any other compound or material that adheres to the surface of particles that absorb light to promote or prevent specific molecular interactions and improve the entry of particles into the pores or follicles will be appreciated. In some embodiments, the particle surface is not modified. Modulation of hydrophilicity against hydrophobicity is carried out by modifying the surfaces of nanoparticles with chemicals known in the art, including silanes, isothiocyanates, short polymers (eg, PEG) or hydrocarbons with the addition of functional groups. Polymer chains (for example, biopolymers such as proteins, polysaccharides, lipids and hybrids thereof; synthetic polymers such as polyethylene glycol, PLGA and others; and synthetic biopolymer hybrids) of different lengths and packing density are useful for varying the adsorption layer / particle slip plane.
Optical absorption. Preferred nanoparticles have optical absorption qualities of about 10 nm to about 10,000 nm, for example, 100-500 nm. In specific embodiments, the nanoparticles have optical absorption useful for excitation by standard laser devices or other light sources. For example, nanoparticles absorb at wavelengths of approximately 755 nm (alexandrite lasers), in the range of approximately 800 to 810 nm (diode lasers), or about 1,064 nm (Nd: YAG lasers). Similarly, nanoparticles absorb intense pulsed light (IPL), for example, in a range of about 500 nm to about 1,200 nm.
Assembly The nanoparticles provided herein may generally contain a collection of non-assembled nanoparticles. By "non-assembled" nanoparticles, it is understood that the nanoparticles of said collection are not linked together through a physical force or chemical bond, either directly (particle particle) or indirectly through an intermediary (for example, particle-cell -particle, particle-protein particle, particle-analyte-particle). In other embodiments, the nanoparticle compositions are assembled in ordered matrices. In particular, said ordered matrices can include any three-dimensional matrix. In some embodiments, only a portion of the nanoparticles are assembled, for example, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 86, 90, 95, 99% or more than 99% of the nanoparticles are assembled in an ordered array. The nanoparticles are assembled by van der Walls attraction, a London force, a hydrogen bond, a dipole-dipole interaction, or a covalent bond, or a combination thereof.
Matrix ordered. The "ordered matrices" can take the form of a macrostructure from individual parts that can be modeled or not modeled in the form of spheres, colloids, pearls, ovals, squares, rectangles, fibers, wires, bars, hearts, thin films or flat surfaces. On the contrary, a "disordered matrix" lacks a substantial macrostructure.
Nanostructures with geometric adjustment. The nanoparticles provided in the present invention can be formed in all forms currently known or that are created in such a way that they absorb light and generate a plasmon resonance at a maximum wavelength or wavelength composition of 200 nm to 10,000 nm. In the non-limiting examples, the nanoparticles are shaped like spheres, ovals, cylinders, squares, rectangles, bars, stars, tubes, pyramids, stars, prisms, triangles, branches or plates or form a flat surface. In the non-limiting examples, the plasmonic particles comprise nanoplates, solid nanowires, hollow nanowires, nanobars, nanowires, nanospheres, nanofibers, nanowires, nanopyramids, nanoprisms, nanoplates or a combination thereof. The plasmonic particles present in the composition comprise a substantial amount of nanostructures with geometric adjustment defined as 5, 10, 15, 25, 50, 75, 80, 85, 90, 95, 98, 99, 99.9 or more than 99, 9% of the particles.
Composition. The nanoparticle is a metal (for example, gold, silver), metallic compound (for example, silver and silica, gold and silica), metallic oxide (for example, iron oxide, titanium oxide), metallic salt (for example potassium oxalate, strontium chloride), intermetallic (for example, titanium aluminum, alnico), electrical conductor (for example, copper, aluminum), electrical superconductor (for example, barium oxide copper barium, bismuth oxide calcium strontium copper ), electric semiconductor (for example, silicon, germanium), dielectric (for example, silica, plastic) or quantum dot (for example, zinc sulphide, cadmium selenium). In non-limiting examples, the materials described are gold, silver, nickel, platinum, titanium, palladium, silicon, gallium. Alternatively, the nanoparticle contains a compound that includes a metal and a dielectric, a metal and a semiconductor, or a metal, a semiconductor and a dielectric.
Covering. Preferably, the composition contains coated nanoparticles.
<img file="ES2717543T3_D0001.tif" />
Biological molecules. The composition may contain a peptide, a nucleic acid, a protein or an antibody. For example, a protein, an antibody, a peptide or a nucleic acid that binds to a protein of a follicular stem cell (for example, keratin 15), a protein, glyomatrix or lipid on the surface of a stem cell or cell, a protein, peptide, glycolytrix of the extracellular matrix or basement membrane.
Fractions loaded. The coated nanoparticles may contain charged fractions whereby said charges mediate the increased or decreased binding to components inside or outside the hair follicle by electrostatic or chemical interactions.
<img file="ES2717543T3_D0002.tif" />
Description of the target tissues.
Topical and dermatological applications. Target tissues for topical and dermatological applications include the surface of the skin, the epidermis and the dermis. Suitable diseases or conditions for treatment with topical and dermatological applications include acne, warts, fungal infections, psoriasis, scar removal, hair removal, hair growth, reduction of hypertrophic or keloid scars, skin inconsistencies (e.g., texture, color, tone, elasticity, hydration) and malignant or non-malignant skin tumors.
As used herein, the term "acne" includes acne vulgaris, as well as other forms of acne and related skin conditions, including summer acne, acne conglobata, cosmetic acne, fulminating acne, keloid acne. from the nape, mechanical acne, necrotic miliary acne, necrotic acne, chloracne, drug-induced acne, scoriated acne, halogen acne, disseminated facial lupus miliar, acne ointment, tar acne and tropical acne.
Subdermal applications Target tissues for subdermal applications include adipose tissue and connective tissue below the integumentary system. Diseases or conditions suitable for treatment with subdermatological applications include wrinkles and tattoos. Other applications include skin rejuvenation and / or renewal of the surface layer, removal or reduction of stretch marks and fat ablation.
Frequently, a specific region of the target tissue is a hair follicle, a sebaceous gland, a merocrine sweat gland, an apocrine sweat gland or a hair erector muscle, within which it is directed to a specific domain. For example, it is directed to the protuberant region of the hair follicle. Because in one embodiment the nanoparticles are useful for thermally ablating hair follicle stem cells for hair removal, it is of particular interest to address regions containing hair follicle stem cells. Therefore, the target tissue region may include a niche of stem cells, bump, sebaceous gland, dermal papilla, cortex, cuticle, inner root sheath, outer root sheath, medulla, Huxley layer, Henle layer or muscle hair erector Each of these regions may contain cells, stem cells, basement membrane, extracellular matrix, growth factors, analytes or other biological components that mediate hair follicle rejuvenation. The interruption or destruction of these components would have a therapeutic effect, for example, slow down or stop the processes that mediate hair growth, prevent sebum secretion of the sebaceous gland, damage or stop tumor cells, reduce the appearance of wrinkles . They can also be directed to structures that are very close to a desired target for ablation, especially when they are able to conduct heat effectively.
Location domains Compositions containing nanoparticles are provided that are preferably located in a domain of a target tissue region of a mammalian subject to which the composition is administered.
Addressing fractions. The nanoparticles can be designed to selectively bind to a domain of the target tissue. For example, the nanoparticles are operatively linked to the domain through a biological fraction, in order to effectively direct the nanoparticles to the target tissue domain. Preferably, the fraction contains a component of a stem cell, a progenitor cell, an extracellular matrix component, a basement membrane component, a hair shaft component, a follicular epithelial component or a non-follicular epidermal component. Biological fractions include proteins such as cell surface receptors, glycoproteins or extracellular matrix proteins, as well as carbohydrates, analytes or nucleic acids (DNA, RNA) as well as membrane components (lipid bilayer components, microsomes).
Offshoring domains. The nanoparticles present in the composition preferably delocalize away from a domain of a region of target tissue. Offshoring domains include specific regions of a tissue in which nanoparticles are not substantially added or, alternatively, removed from the domain more efficiently. In preferred embodiments, the delocalization domain is a non-follicular epidermis, a dermis, a component of a hair follicle (for example, a capillary stem cell, a niche of stem cells, a bump, a sebaceous gland, a dermal papilla, a cortex, a cuticle, an inner root sheath, an outer root sheath, a medulla, a Huxley layer, a Henle layer, a hair erector muscle), a hair follicle infundibulum, a sebaceous gland, a component of a sebaceous gland, a sebum, a component of a sebum or sebum.
Energy sources. Non-linear excitation surface plasmon resonance sources are provided here, which include various light sources or optical sources. Examples of light sources include a laser (ionic laser, semiconductor laser, Q switched laser, free-running laser or fiber laser), light emitting diode, lamp, sun, fluorescent light source or an electroluminescent light source . Typically, the energy source is capable of emitting radiation at a wavelength of about 100, 200, 300, 400, 500, 1,000, 2,000, 5,000 nm to about 10,000 nm or more. The non-linear excitation surface plasmon resonance source is capable of emitting electromagnetic radiation, ultrasound, thermal energy, electrical energy, magnetic energy or electrostatic energy. For example, energy is radiation at an intensity of approximately 0.00005 mW / cm2 to approximately 1,000 TW / cm2. The optimum intensity is chosen to induce high thermal gradients from plasmonic nanoparticles in regions of approximately 10 micrometers to hundreds of micrometers in surrounding tissue, but it has a minimal residual effect on the heating tissue in which the particles do not reside within a radius of approximately 100 micrometers or more of the nanoparticle. In certain embodiments, a differential heat gradient between the region of target tissue and other tissue regions (e.g., the skin) is greater than 2 times, 3 times, 5 times, 10 times, 15 times, 20 times, 50 times , 100 times or more than 100 times.
The energy can be adjusted by controlling thermal heat gradients on the skin surface with a thermal / infrared camera. As demonstrated here, the methods and systems of the present description provide superior efficacy when a surface plasmon is generated on the nanoparticles by the action of radiation. Typically, plasmon is generated in the form of a photon or, alternatively, in the form of two photons, in the form of multiple photons, in stepped form or in the form of upward conversion.
Radiation supply. Physical means of supplying energy from the nonlinear excitation surface plasmon resonance source to the target tissue region include a fiber, waveguide, a tip of contact or a combination thereof.
Optical sources include a CW optical source or a pulsed optical source, which can be an optical source of a single polarized wavelength (or, alternatively, non-polarized) capable of emitting radiation at a frequency of about 200 nm to about 10,000 nm . Alternatively, the optical source is a multi-polarized wavelength (or, alternatively, non-polarized) optical source capable of emitting radiation at a wavelength of about 200 nm to about 10,000 nm. The pulsed optical source is generally capable of emitting pulsed radiation at a frequency of about 1 Hz to about 1 THz. The pulsed optical source is capable of a pulse of less than one millisecond, microsecond, nanosecond, PS, or fempt second in duration. The optical source can be coupled to a skin surface cooling device to reduce heating of particles or structures on the skin surface and focus heating to components within follicles or tissue structures in deeper layers.
Compositions containing nanoparticles. In order to provide optimal dermal penetration in the target tissue, plasmonic nanoparticles in certain embodiments are formulated in various compositions. Preferably, the nanoparticles are formulated in compositions containing 1-10% v / v surfactants (for example, sodium dodecyl sulfate, sodium lauret 2-sulfate, ammonium lauryl sulfate, octech-1 / deceth-1 sodium sulfate). Surfactants alter and emulsify sebum or other hydrophobic fluids to allow improved targeting of hydrophilic nanoparticles in the hair follicle, infundibulum, sebaceous gland or other skin regions. Surfactants also decrease the free energy necessary to deliver hydrophilic nanoparticles in small hydrophobic grooves such as the space between the hair shaft and the follicle or in the sebaceous gland. Compositions containing nanoparticles may also include emulsions at various concentrations (1-20% w / v) in aqueous solutions, silicone / oil solvents, propylene glycol or creams (eg, alcohols, oils, paraffins, colloidal silicas). In other embodiments, the formulation contains a degradable or non-degradable polymer, for example, synthetic polylactide / coglycolide copolymer, porous laurilactam / caprolactam nylon copolymer, hydroxyethylcellulose, polyelectrolyte monolayers, or alternatively, in natural hydrogels such as hyaluronic acid, Jelly and others. In further embodiments, a PLGA in hydrogel, PEG acrylate is included in the formulation. Alternatively, a matrix component such as silica, polystyrene or polyethylene glycol is provided in the formulation. Other formulations include surfactant components, a lipid bilayer, a liposome or a microsome. A nanoparticle can comprise a particle of larger micrometer size.
Effective doses As described herein, an effective dose of nanoparticle containing compositions includes a quantity of particles required, in some aspects, to generate an effective heat gradient in a region of target tissue, so that a portion of the region of target tissue is subjected to the thermal energy action of excited nanoparticles. A "minimum effective dose" is the smallest number or lowest concentration of nanoparticles in a composition that are effective in achieving the desired biological, physical and / or therapeutic effect. Preferably, the plasmonic nanoparticles have an optical density OD of 10 to 1,000 in one or a plurality of peak resonance wavelengths.
Cosmetically acceptable carriers. Cosmetic or pharmaceutical compositions are provided with a plurality of plasmonic nanoparticles and a cosmetic or pharmaceutically acceptable carrier. Generally, the carrier and the composition should be suitable for topical administration to the skin of a mammalian subject, so that the plasmonic nanoparticles are present in an amount effective for the selective thermomodulation of a skin component. Preferably, the nanoparticles are formulated with a carrier containing 1-10% v / v surfactants (e.g., sodium dodecyl sulfate, sodium lauret 2-sulfate, ammonium lauryl sulfate, octech-1 / deceth-1 sodium sulfate) for allow the breakdown of the skin's epidermis barrier, emulsify sebum, improve the mixing of hydrophilic nanoparticles with hydrophobic solutions and reduce entropic barriers to deliver hydrophilic particles to hydrophobic regions of the skin (for example, between the capillary stem and the surrounding sheath or follicle). In some embodiments, the carrier contains a polar or non-polar solvent. For example, suitable solvents include alcohols (for example, n-butanol, isopropanol, n-propanol, ethanol, methanol), hydrocarbons (for example pentane, cyclopentane, hexane, cyclohexane, benzene, toluene, 1,4-dioxane), chloroform, diethyl ether, water, water with propylene glycol, acids (for example, acetic acid, formic acid), bases, acetone, isooctanes, dimethyl sulfoxide, dimethylformamide, acetonitrile, tetrahydrofuran, dichloromethane, ethyl acetate, tetramethylammonium hydroxide, Isopropanol and others. In other embodiments, a stabilizing agent such as antioxidants, prevents unwanted oxidation of the materials, sequestrants, forming chelate complexes and inactivating traces of metal ions that would otherwise act as catalysts, emulsifiers, ionic or non-ionic surfactants, cholesterol or phospholipids, for the stabilization of emulsions (for example, egg yolk lecithin, sodium stearoylactylate, sodium bis (2-ethylhexyl sulfosuccinate (AOT)), UV stabilizers, protective materials, especially plastics, from the harmful effects of ultraviolet radiation. In other embodiments, a cosmetically acceptable carrier is generated such that the nanoparticles are substantially in a suspension.
Other components are also optionally included, including an emulsion, polymer, hydrogel, matrix, lipid bilayer, liposome or microsome. Additionally, the inclusion of a detectable dye (eg, a pigment), a fragrance, a humectant and / or a skin protector is optional. In some examples, the formulation has a viscosity above, below or within 0.1-1,000 measured in millipascal-seconds (mPas).
The amounts of nanoparticles per milliliter in a composition are subject to modification for specific binding and can range from 109 to 1018 particles, but generally about 1011 to 1013 nanoparticles per milliliter. In certain embodiments where an increase in the concentration of nanoparticles to a target region is desired, the compositions contain concentrations of particles with optical densities of OD 10 to OD 1,000, or optical densities greater than OD 1,000. In some embodiments, these correspond to concentrations of approximately 0.1-10% w / w or more of nanoparticles.
Prior to the application of nanoparticle formulations, the skin and hair follicles can be pretreated to increase the supply of nanoparticles to a target region. In some embodiments, the hair is cut or removed by shaving, hair removal, surface exfoliation with cyanoacrylate, treatment with calcium thioglycolate or other techniques to remove the hair shaft and / or plugs of the hair follicle and create a space in the hair. that nanoparticles can accumulate. The holes of active or inactive follicles can be blocked by plugs formed of corneocytes and / or other material (for example, cellular debris, soot, hydrocarbons, cosmetics). In some embodiments, pretreatment with surface exfoliation including mechanical exfoliation (for example, salt or microdermabrasion exfoliation) and chemical exfoliation (for example, enzymes, alpha hydroxy acids or beta hydroxy acids) removes follicle orifice plugs to increase targeting. of nanoparticle formulations to target regions within the hair follicle.
In some embodiments, the nanoparticle formulations are formulated for application by a sponge applicator, cloth applicator, direct contact by a gloved hand or hand, atomizer, aerosol, vacuum suction, high pressure air flow or liquid flow High pressure roller, brush, flat surface, semi-flat surface, wax, ultrasound and other sonic forces, mechanical vibrations, hair shaft manipulation (including pull, massage), physical strength, thermal manipulation and other treatments. In some embodiments, nanoparticle formulation treatments can be performed alone, in combination, sequentially or repeated 1-24 times. In other embodiments, plasmonic nanoparticles are capable of selectively locating a first skin component, where physical massage or pressure, ultrasound or heat increases the selective location of the nanoparticles to this first component. In addition, the nanoparticles can be selectively separated from components of the skin other than the first component, such removal is done with acetone, alcohol, water, air, skin exfoliation, chemical peel, waxing or reduction of the plasmonic compound. In addition, in some embodiments the nanoparticles have a coating layer to increase the solubility of the nanoparticles in the carrier and / or reduce the "adhesiveness" and accumulation in non-target areas. The object described herein also provides embodiments in which at least a portion of an outer surface of the nanoparticle is modified, such as to include a layer of a polymer, polar monomer, non-polar monomer, biological compound, metal (by example, thin metal film, metal compound, metal oxide or metal salt), a dielectric or a semiconductor. Alternatively, the modification of the outer surface is polar, non-polar, charged, ionic, basic, acidic, reactive, hydrophobic, hydrophilic, agonist or antagonist. In certain embodiments when at least one dimension of at least one nanoparticle within a solution of plasmonic nanoparticles is less than 50-100 nm, the surface of the nanoparticle may be coated with a matrix (eg silica) of 10-100 nm of thickness or more to increase said dimension or particle to 50-100 nm or more. This larger size can increase the supply of all nanoparticles to a target region (for example, hair follicle) and limit the supply to non-target regions (for example, dermis).
Means of penetration
Preferably, the compositions of the present disclosure are administered topically. Means are provided herein to redistribute plasmonic particles from the surface of the skin to a dermal tissue component that includes a hair follicle, a component of a hair follicle, a follicular infundibulum, a sebaceous gland or a component of a sebaceous gland using high frequency ultrasound, low frequency ultrasound, massage, iontophoresis, high pressure air flow, high pressure liquid flow, vacuum, Pre-treatment with fractional photothermolysis or dermabrasion laser, or a combination thereof. For example, the compositions can be administered by using a sponge applicator, fabric applicator, atomizer, aerosol, vacuum suction, high pressure air flow, direct contact of high pressure liquid flow by manual ultrasound and others. sonic forces, mechanical vibrations, hair shaft manipulation (including pull, massage), physical strength, thermal manipulation or other treatments. The nanoparticle formulation treatments are performed alone, in combination, sequentially or repeated 1-24 times.
Cosmetic and therapeutic uses of plasmonic nanoparticles.
In general terms, the applicant or applicants have created systems and methods for the cosmetic and therapeutic treatment of dermatological conditions, diseases and disorders using nanoparticle-based treatment methods.
Acne treatment
Acne is caused by a combination of diet, hormonal imbalance, bacterial infection (Propionibacterium acnes), genetic predisposition and other factors. The nanoparticle-based methods and systems described herein for the treatment of acne are capable of targeting the causative regions of the dermis, sebaceous gland and hair follicle, and therefore have advantages compared to existing techniques known in the art, including chemical treatment (peroxides, hormones, antibiotics, retinoids and anti-inflammatory compounds), dermabrasion, phototherapy (lasers, treatment with blue and red light, or photodynamic treatment), or surgical procedures.
In particular, laser-based techniques are becoming an increasingly popular acne treatment, but a substantial limitation is the lack of selective absorption properties among natural pigments (eg, fat, sebum) for light wavelengths. specific such that selective heating of a cell, structure or tissue component, particularly in the sebaceous glands, infundibulum and regions of the hair follicle, It is not achieved without heating the adjacent tissue outside the target. The nanoparticles described herein provide a significantly higher photothermal conversion than natural pigments, which allows laser energy to be focused on specific cells, structures or tissue components within the sebaceous gland, infundibulum, or regions of the hair follicle for damage. selective photothermal.
The use of the materials and techniques described here can provide acne treatments that last longer than existing methodologies. In certain embodiments, the adjusted selective ablation of the sebaceous or infundibular gland is achieved as described herein. In particular, plasmonic nanoparticles are specifically located in regions of hair follicles at or near the sebaceous or infundibular gland.
Plasmonic nanoparticles exhibit strong absorption at the wavelengths emitted by standard laser hair removal devices (for example, 755 nm, 810 nm, 1,064 nm) with respect to the surrounding epidermal tissue. Therefore, irradiation of laser-directed plasmonic nanoparticles induces thermal radiation from the particles to the adjacent sebum, the sebaceous gland, the infundibulum and other acne-causing agents.
Hair removal
The nanoparticle-based methods and systems described herein for skin treatment have advantages compared to existing techniques known in the state of the art, including laser-based techniques, chemical techniques, electrolysis, electromagnetic wave techniques and mechanical techniques. (for example, waxing, tweezers). Such techniques do not adequately provide permanent hair removal across a wide range of subjects. In particular, subjects who have light or medium pigmented hair are not adequately helped by these techniques, which suffer from side effects including pain and lack of beneficial cosmetic effects including hair removal. Laser-based techniques are popular in a variety of applications, but a substantial limitation is the lack of selective absorption properties among natural pigments (eg, melanin) for specific wavelengths of light, so that selective heating of a tissue cell, structure or component is reached without heating adjacent tissues outside the target. The nanoparticles described herein provide a significantly higher photothermal conversion than natural pigments, allowing laser energy to focus on specific tissue cells, structures or components to cause selective photothermal damage.
A more permanent reduction or elimination of all hair types is provided here, in relation to the hair removal treatments known in the art. In certain embodiments, adjusted selective ablation of the capillary stem and destruction of stem cells in the protuberant region is provided, as described herein. In particular, plasmonic nanoparticles are specifically located in regions of hair follicles in or near the protuberant region, a domain rich in hair follicle stem cells. In addition, plasmonic nanoparticles are located near ~ 50-75% of the hair shaft structure.
Plasmonic nanoparticles exhibit strong absorption at the wavelengths emitted by standard laser hair removal devices (for example, 755 nm, 810 nm, 1,064 nm) with respect to the surrounding epidermal tissue. Therefore, irradiation of plasmonic nanoparticles directed with laser light induces thermal radiation of the particles to adjacent stem cells (or in some cases, to the very architecture of the capillary stem), resulting in cell death and an alteration of the pathway normal regenerative
Malignant and non-malignant skin tumors
Laser therapies for the prevention and treatment of non-malignant, malignant, melanoma and non-melanoma skin cancers have largely focused on photodynamic therapy approaches, so photosensitive porphyrins are applied to the skin and used to locate laser light, produce reactive oxygen species and destroy cancer cells through toxic radicals. For example, 5-ALA combined with laser treatment has been approved by the FDA for the treatment of actinic keratoses of nonmelanoma skin cancer, and is used without markers for the treatment of widely disseminated basal cell carcinomas (BCC) , surgically intractable or recurrent. However, this procedure causes patients to experience photosensitivity, burning, scaling, scarring, hypo and hyperpigmentation and other side effects due to non-specific transdermal uptake of porphyrin molecules. The nanoparticles described herein provide a significantly higher photothermal conversion than natural pigments and dyes, allowing laser energy to be focused on specific tissue cells, structures or components for selective thermomodulation.
The use of the materials and techniques described here can provide cancer treatments of greater degree and duration than existing methodologies. In certain embodiments, selective ablation of specific target cells was adjusted as described herein. In particular, plasmonic nanoparticles are specifically located for regions of hair follicles where follicular protruding stem cells arise to form nodular basal cell carcinomas and other carcinomas. Plasmonic nanoparticles can also be administered to other target cells that cause tumors, for example, the interfollicular epithelium, which includes the cell of origin for superficial basal cell carcinomas.
Plasmonic nanoparticles exhibit strong absorption at the wavelengths emitted by standard laser hair removal devices (for example, 755 nm, 810 nm, 1,064 nm) with respect to the surrounding epidermal tissue. Therefore, irradiation of laser-directed plasmonic nanoparticles induces thermal radiation of the particles to the keratinocyte, melanocyte, follicle protruding stem cell, cancer cell or adjacent cancer cell precursor, resulting in cell death or inhibited cell growth for prevention and cancer treatment.
Subdermal applications Target tissues for subdermal applications include adipose tissue and connective tissue below the integumentary system. Diseases or conditions suitable for treatment with subdermatological applications include wrinkles and tattoos. Other applications include skin rejuvenation and / or renewal of the surface layer, removal or reduction of stretch marks and fat ablation.
Vascular applications Target tissues for vascular applications include arteries, arterioles, capillaries, veins and venules. Diseases or conditions suitable for treatment with vascular applications include spider veins, leaking valves and vascular stenosis. In particular, venous abnormalities represent a substantial proportion of cosmetic diseases or conditions that affect the vasculature. Individuals with vein abnormalities such as spider veins or defective venous valves suffer from pain, itching, or undesirable aesthetics.
In addition, there are several indications for which ablation of other vessels including arteries, arterioles or capillaries could provide therapeutic or cosmetic benefits including: 1) vasculature ablation by providing fat pads and / or fat cells, 2) vasculature ablation that supports tumor / cancer cells, 3) vascular birthmark ablation (port wine stains, hemangiomas, macular spots ), and 4) any other indication by which vessel ablation mediates tissue destruction and apoptosis or necrosis of cells supported by those vessels with therapeutic or cosmetic benefit. Methods for using the compositions described herein for the selective destruction of a component or components of the veins from focal or diffusely distributed plasma nanoparticles in the blood are provided herein. Plasmonic nanoparticles are combined with a pharmaceutically acceptable carrier as described above and are introduced into the body by intravenous injection. The nanoparticles diffuse in the blood and, in some embodiments, are located in specific vascular tissues. Subsequently, the nanoparticles are activated with laser or light-based systems as is known in the art for the treatment of skin conditions such as hair removal or spider vein ablation. Alternatively, laser or light systems based on image-guided or unguided fiber optic guides can be used to ablate the vessel or blood components in larger veins. In one embodiment, a device with dual functions can be used to inject nanoparticles and administer light through an optical waveguide. Activated nanoparticles heat the blood and adjacent tissue (vessels, vessel walls, endothelial cells, components on or in endothelial cells, components comprising endothelial basement membrane, mesenchymal support tissues, cells or cellular components around the vessel, blood cells, blood components, other blood components) at ablative temperatures (38-50 degrees C or higher).
A composition is provided herein comprising a pharmaceutically acceptable carrier and a plurality of plasmonic nanoparticles in an amount effective to induce thermomodulation of a region of vascular or intravascular target tissue with which the composition is contacted intravenously. In addition, the plasmonic nanoparticle composition may comprise a microvascular targeting medium selected from the group consisting of antibodies and ligands of antimicrovascular endothelial cells for surface receptors of microvascular endothelial cells. A method is also provided for thermoablation of a target vascular tissue in a mammalian subject, comprising the steps of contacting a region of the target vascular tissue with a composition comprising a plurality of plasmonic nanoparticles and a pharmaceutically acceptable carrier under such conditions. that an effective amount of plasmonic nanoparticles is located in a domain of the target vascular region; and exposing the target tissue region to energy supplied from a nonlinear excitation surface plasmon resonance source in an amount effective to induce thermoablation of the target vascular region domain.
Oral and nasal applications. Target tissues for oral applications include the mouth, nose, pharynx, larynx and trachea. Diseases or conditions suitable for treatment with vascular applications include oral cancer, polyps, throat cancer, nasal cancer and Mounier-Kuhn syndrome.
Endoscopic applications Target tissues for endoscopic applications include the stomach, small intestine, large intestine, rectum and anus. Suitable diseases or conditions for treatment with vascular applications include gastrointestinal cancer, ulcerative colitis, Crohn's disease, irritable bowel syndrome, celiac disease, short bowel syndrome or an infectious disease such as giardiasis, tropical sprue, tapeworm infection, ascariasis , enteritis, ulcers, Whipple's disease and megacolon.
Thermomodulation methods. Methods for thermomodulating a region of target tissue are provided. A nanoparticle composition comprising a plurality of plasmonic nanoparticles under conditions such that an effective amount of the plasmonic nanoparticles is located in a domain of the target tissue region; and exposing the target tissue region to energy supplied from a nonlinear excitation surface plasmon resonance source in an amount effective to induce thermomodulation of the target tissue region domain.
Removal of non-specific bound nanoparticles. The removal of nanoparticles located on the surface of the skin can be done by contacting the skin with acetone, alcohol, water, air, a debridement agent or wax. Alternatively, physical debridement can be performed. Alternatively, a reduction of the plasmonic compound can be performed.
Amount of energy supplied. The skin is irradiated at a fluence of 1-60 joules per cm2 with laser wavelengths of approximately, for example, 750 nm, 810 nm, 1,064 nm, or other wavelengths, particularly in the infrared light range. Various continuous to pulsed repetition rates are used, for example, at 1-10 Hz, 10-100 Hz, 100-1,000 Hz. Although some energy is reflected, it is an advantage of the matter described here that a substantial amount of energy is absorbed by the particles, with a smaller amount absorbed by the skin. The nanoparticles are supplied to the hair follicle, infundibulum or sebaceous gland at a concentration sufficient to absorb, for example, 1.1-100 times more energy than other skin components of similar volume. This is achieved in some embodiments by having a concentration of particles in the hair follicle with absorbance at the laser peak of 1.1-100 times with respect to other skin components of similar volume.
To allow the adjustable destruction of target skin structures (e.g., sebaceous glands, infundibulum, hair follicles), light absorbing nanoparticles are used together with a laser or other excitation source of the appropriate wavelength. The laser light can be applied continuously or in pulses with a single or multiple pulses of light. The heating intensity and the distance over which photothermal damage will occur are controlled by the intensity and duration of exposure to light. In some embodiments, pulsed lasers are used in order to provide localized thermal destruction. In some of such embodiments, pulses of varying durations are provided to locate regions of thermal damage within 0.05, 0.1, 0.5, 1, 2, 5, 10, 20, 30, 50, 75, 100, 200, 300, 500, 1,000 microns of the particles. The pulses are at least fempt seconds, picoseconds, microseconds or milliseconds in duration. In some embodiments, the maximum temperature obtained in the tissue from the heating of nanoparticles is at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300 or 500 degrees Celsius In some embodiments using pulsed heating, high peak temperatures are obtained locally within the hair without raising the macroscopic tissue temperature by more than 0.1, 0.5, 1, 2, 3, 4, 5, 7, 9, 12 , 15, or 20 degrees Celsius. In some embodiments, short pulses (100 nanoseconds - 1,000 microseconds) are used to direct very high transient heat gradients in and around the target skin structure (e.g., sebaceous gland and / or hair follicle) from embedded particles to locate damage in the vicinity of the location of the particle. In other embodiments, longer pulse lengths (1-500 ms) are used to direct heat gradients farther from the target structure to locate thermal energy to stem cells in the protuberant region or other components greater than 100 pm away from the localized particles. Fluences of 1-30 joules per cm2 are generally sufficient to thermally ablate follicles that have high concentrations of particles and therefore greater absorbency than the skin (for example, 1.1 - 100 times per volume of skin absorbency). These creeps are often lower than those currently used (for example, diode: 25-40 J / cm2, Alexandrite: 20 J / cm2, Nd: YAG: 30-60 J / cm2) and that produces less damage to non-follicular regions, and potentially less pain.
Plasmon resonance systems. Plasmon resonance systems are provided that contain a surface that includes a plurality of plasmonic nanoparticles, and a source of nonlinear excitation. Preferably the surface is a component of the skin intended for cosmetic or therapeutic treatment (for example, protuberant region for hair removal, infundibulum or sebaceous gland for acne prevention). Also provided as a component of the system is a means to deliver plasmonic nanoparticles to the surface of the skin, such as an applicator, an atomizer, an aerosol, vacuum suction, a high pressure air flow or a liquid flow to high pressure. Means are also provided for locating plasmonic nanoparticles in a skin component (e.g., hair follicle, protuberant region, sebaceous gland, infundibulum). Useful surface supply means include a device that generates high frequency ultrasound, low frequency ultrasound, heat, massage, contact pressure, or a combination thereof.
Additionally, systems containing a means of removal to remove nanoparticles on a non-follicular portion of the skin are provided. Removal means include at least one of acetone, alcohol, water, air, chemical peel, wax, or a compound that reduces the plasmonic compound.
In addition, the systems of the present description provide a non-linear excitation source that generates a continuous wave optical source or a pulsed optical source. Alternatively, the non-linear excitation source is capable of generating electromagnetic radiation, ultrasound, thermal energy, electrical energy, magnetic energy or electrostatic energy. Systems are provided in which the non-linear excitation source is capable of irradiating the nanoparticles with an intensity of about 0.00005 mW / cm2 to about 1000 TW / cm2 In addition, the non-linear excitation source is capable of operating in the form of a photon, of two photons, of several photons, in stages or of upward conversion. In today's systems, a fiber, a waveguide, a contact tip or a combination thereof can be used.
In some embodiments, the system contains a control device such as a temperature sensor or a thermal energy detector. In other embodiments, the systems also contain a controller means for modulating the non-linear excitation source (for example, a feedback loop controller). In a related embodiment, the system contains a means for detecting a surface temperature or a target tissue adjacent to the surface, in which the controller means modulates the intensity of the non-linear excitation source and / or the duration of The Excitement. In such embodiments, the control means preferably modulates the intensity of the nonlinear excitation source such that a first component of the hair follicle undergoes selectively thermoablation with respect to a second component of the hair follicle. In other embodiments, a cooling device is contacted directly with the skin during irradiation to minimize heating of the nanoparticles or skin on the surface, while the nanoparticles that have penetrated deeper into the follicle, skin or skin. Sebaceous gland is heated to temperatures that selectively ablate adjacent tissues.
The skin is an example of objective tissue. The skin preferably contains a hair follicle and / or a sebaceous gland, where the non-linear source of excitation generates energy that results in the heating of the skin in an amount effective to induce thermodulation of a hair follicle, an infundibulum, a sebaceous gland or a component thereof, such as by sufficient heating to cause the skin temperature to exceed 37 ° C, such as 38 ° C, 39 ° C, 40 ° C, 41 ° C, 42 ° C, 43 ° C , 44 ° C, 45 ° C, 46 ° C, 47 ° C, 48 ° C, 49 ° C, up to about 50 ° C or more. Methods of formulation Methods for formulating the nanoparticles of the present disclosure are also provided in a form suitable for use as described herein. In particular, nanoparticle compositions are generated by:
a) formation of a first mixture containing a plurality of nanoparticles and a first solvent;
b) exchange of the first solvent for a second solvent to form a second mixture; Y
c) combination of the second mixture and a cosmetic or pharmaceutically acceptable carrier,
thus forming a nanoparticle composition.
The exchange stage is optionally performed using liquid chromatography, a solvent exchange system, a centrifuge, precipitation or dialysis. Preferably, the nanoparticles are superficially modified by a controlled reduction stage or an oxidation stage. Said surface modification may involve a coating step, such as the adsorption of a monomer, polymer or biological entity to a surface of the nanoparticle. Typically, the coating step involves contacting the nanoparticles with an oxidative environment. In addition, the coating step may include polymerization of monomers to create a polymeric coating.
The methods described herein may also include the steps of dissolving the nanoparticles in a non-polar solvent and subsequently mixing the dissolved nanoparticles with a polar solvent to encapsulate the nanoparticles in an emulsion. In addition, the addition of surfactants (e.g., sodium dodecyl sulfate, sodium lauret 2-sulfate, ammonium lauryl sulfate, octech-1 / deceth-1 sodium sulfate) can be used at concentrations of 0.1-10% to interrupt the epidermal skin barrier, emulsify the sebum and allow an improved mixture of hydrophilic nanoparticles in aqueous solutions. In addition, a concentration of the nanoparticles can be employed such as by centrifugation or lyophilization. In addition, the nanoparticles can be pretreated with heat or radiation. The optional stage of conjugation of a biological entity or plurality of biological entities with the nanoparticles is also provided. Such a conjugation step may involve a thiol, amine or carboxyl linkage of the biological entities with the nanoparticles.
Diseases and disorders The present disclosure can be used in human skin (or other animal) for the treatment of wrinkles and other changes related to photoaging or chronological aging (generally called skin rejuvenation), for the treatment of diseases including skin diseases, for the reduction of acne and related disorders such as rosacea, folliculitis, pseudofolliculitis barbae or proliferative or papulo-squamous disorders such as psoriasis, for stimulation or reduction of hair growth, and for the reduction of cellulite, warts, hypopigmentation such as port wine stains (PWS, nevus flammeus), birthmarks, hyperhidrosis, varicose veins, pigmentary problems, tattoos, vitiligo, melasma , scars, stretch marks, fungal infections, bacterial infections, dermatological inflammatory disorders, musculoskeletal problems (for example, tendonitis or arthritis), to improve the healing of surgical wounds, cauterization therapy to improve healing and / or reduce and minimize scars, improve circulation within the skin and the like.
The present description may also be useful for improving wound healing, including, but not limited to chronic skin ulcers, diabetic ulcers, thermal burn injuries, ulcers or viral disorders, periodontal disease and other dental diseases. The present disclosure, in certain embodiments, is also useful for improving the effects of devices that create an injury or wound in the process of performing cosmetic surgery including non-ablative thermal wound techniques to treat skin wrinkles, scars, stretch marks and other skin disorders. . In such circumstances, it may be preferable to use conventional non-ablative heat treatments in combination with the methods of the present disclosure. The current application, in certain embodiments, is used together with microabrasion or surface abrasion, dermabrasion or enzymatic or chemical peeling of the skin or topical cosmeceutical applications, with or without application of nanoparticles to improve treatment, since the removal of the stratum corneum ( and possibly additional epithelial layers) may be beneficial for some treatment regimen. The methods of the present disclosure are particularly applicable, but not limited to, the treatment of acne, hair removal, hair growth / hair follicle stimulation, reduction / prevention of malignant and non-malignant skin tumors, and skin rejuvenation. , as described here.
The dermatologically therapeutic methods described in the present invention can be formed using only nanoparticle irradiation, nanoparticle irradiation in combination with nano or microparticles or irradiation of nanoparticles with a composition comprising nano or microparticles and one or more therapeutic agents. Said nanoparticle irradiation may be produced by any known nanoparticle generator, and is preferably a focused nanoparticle generator capable of generating and radiating waves of focused nanoparticles.
Examples
Example 1. Generation of plasmonic nanoparticles for thermomodulation.
Plasmonic nanoparticles are generated, including nanobars, hollow nanowires, silicon nanowires, nanoplates, nanoarroces, nanowires, nanopyramids, nanoprisms, nanoplates and other configurations described herein and known to those skilled in the art, in size ranges of 1- 1,000 nm under conditions such that the surface properties that facilitate deep follicular penetration. The surface properties can be varied in one or multiple (2, 3, or 4) different dimensions to increase the concentration of nanoparticles in a target tissue domain. Penetration into follicular openings of 10-200 | jm can be maximized using the nanoparticles described herein. In this case, nanoparticles sized in the range of about 10 to about 100 nm are generated, and are preferably assembled or formulated in multi-particle structures having a size in the range of 100-300 nm. Alternatively, a coating (eg silica) is grown on single particle structures to increase the particle size in the range of 100-300 nm or more.
Surface modified plasmonic nanoparticles. An example of preparation of surface modified plasmonic nanoparticles is provided as follows. The plasmonic nanoparticles are synthesized with a stable coating of cetryltrimethylammonium bromide (CTAB) and are concentrated from an optical density of OD 10 to 100, 200, 300, 400 or 500 through one to three centrifugation cycles at 16,000 rcf , with decantation of the supernatant. Alternatively, CTAB coated nanoparticles are concentrated and resuspended in 250 Amol / L of 5 kDa-thiol methyl polyethylene glycol (PEG) to obtain PEG coated nanoparticles. Verification that the polymeric stocks of PEG are completely reduced is performed using spectrophotometry to measure the thiol activity of the polymeric thiols with 5,5-dithiobis (2-nitrobenzoic acid) against a DTT gradient. The solution of methyl-PEG-thiol and CTAB coated nanoparticles is mixed at room temperature for 1 h and then dialyzed against 5 kDa MWCO in 4 liters of distilled water for 24 h. The dialyzed samples are processed through 100 kDa filters to remove excess polymer. The quantification of the number of PEG polymers per particle is performed by surface modifying nanoparticles with amino-PEG-thiol polymer and quantification of the number of amines with an SPDP assay. For test formulations, solutions with OD 100 of CTAB-coated plasmonic nanoparticles in distilled water are made, and PEG-coated DO 100 plasmonic nanoparticles are made in distilled water, ethanol, DMSO or mineral oil. Plasmonic nanoparticles with silica cores are created by reacting nanoparticles with silicates such as tetra-ethyl-ortho-silicate (TEOS), sodium silicate, aminopropyltriethoxysilane (APTS), etc., up to thicknesses of 5-50 nm or more. Control formulations, only with potador, do not contain nanoparticles.
Embedded Nanoparticles The nanoparticles are embedded (or encapsulated) in materials, allowing the generation of a wide range of sizes to adjust their size. It has been shown that particle sizes in the 100-2,000 nm range penetrate the hair follicle without penetrating the dermis. Nanoparticles they are encapsulated in silica, a synthetic polylactide / coglycolide copolymer, porous nylon laurilactam / caprolactam copolymer, hydroxyethylcellulose, polyelectrolyte monolayers, or alternatively, in natural hydrogels such as hyaluronic acid, without significantly altering plasmon resonance properties. The nanoparticles are embedded within 100-2,000 nm materials without covalent bonding or by cross-linking of amines, carboxyls or other fractions on the surface of the nanoparticles to the polymer structure. The 100-2,000 nm material surface can be modified for optimum zeta potential, hydrophilicity / hydrophobicity, and / or adsorption layer through the techniques described herein. In addition, the shape of the polymer's aspect ratio can be modified from low to high to increase the concentrations and penetration depths of the embedded plasmonic nanoparticles. The nanoparticles advantageously have an aspect ratio greater than about 1.
Example 2. Formulation of thermoablative plasmonic nanoparticles for topical administration.
The nanoparticles are generated as in Example 1 using an appropriate solvent (for example, water, ethanol, dimethyl sulfoxide). The mixture comprising a plurality of nanoparticles in water is concentrated to approximately OD 100-500 and changed to a new solvent by liquid chromatography, a solvent exchange system, a centrifuge, precipitation or dialysis. The solvent may include an alcohol (for example, n-butanol, isopropanol, n-propanol, ethanol, methanol), a hydrocarbon (eg, pentane, cyclopentane, hexane, cyclohexane, benzene, toluene, 1,4-dioxane), chloroform, diethyl ether, water, an acid (for example, acetic acid, formic acid), a base, acetone, dimethyl sulfoxide, dimethylformamide, acetonitrile, tetrahydrofuran, dichloromethane or ethyl acetate. The new solvent is combined with a cosmetic or pharmaceutically acceptable carrier, thus forming a nanoparticle composition. Generally, the particles and the carrier will form an emulsion.
Plasmonic nanoparticle formulations are provided that amplify or accelerate the penetration of the nanoparticles into the hair follicles. In some embodiments, the nano and microemulsions facilitate partitioning into lipid-rich skin compartments such as the hair follicle. In some embodiments, the nanoparticles are formulated in compositions containing 0.5-2% v / v of surfactants to allow breaking the epidermal skin barrier, sebum emulsion and an improved mixture of hydrophilic nanoparticles in hydrophobic solutions or directed to the hydrophobic space on the skin (for example, between the hair shaft and the surrounding follicle). Nanoparticle formulations are also provided at various concentrations (1-20% w / v) in aqueous solutions, silicone / oil solvents, propylene glycol or creams (for example, containing alcohols, oils, paraffins, colloidal silicas). In some embodiments, the light absorbing nanoparticles are used in solutions that have a pH, a temperature, an osmolyte concentration, a viscosity, a volatility and other characteristics adapted to improve the entry of light absorbing nanoparticles into the hair follicles.
The formulations are prepared to maximize the stability of the nanoparticles (degree of aggregation in solution), concentration of nanoparticles and absorbance of nanoparticles (degree of laser induced heating at different concentrations).
When plasmonic nanoparticle formulations are illuminated with a clinical laser with a wavelength coinciding with the maximum absorption wavelength of the particle, the formulation heats at thermoablative temperatures more rapidly and to a greater extent than conventional absorbent clinical dyes. Figure 2 compares the temperature profile of plasmonic particles (maximum absorption wavelength of 1,020 nm) with conventional clinical dyes, carbon lotion, meladin spray and indocyanine green after exposure to 1,064 nm, 20 J / cm2, 55 ms laser pulses. The temperature rise caused by the pulsed laser light of 1,064 nm was more than 2.5 times higher for the plasmonic solution, compared to conventional clinical dyes used at the same dilution (1: 1,000 dilution of the clinical concentration, where the Clinical concentrations are as follows: 200 mg / ml, meladin 1 mg / ml, indocyanine green 5 mg / ml).
Example 3. Use of plasmonic nanoparticles for hair thermomodulation.
Individuals who have blond, red, gray or slightly colored hair are not adequately treated with existing light-based hair removal techniques. Methods for using the compositions described herein are provided herein for the selective removal or reduction of untreated blond, red, gray or slightly colored hair. Plasmonic nanoparticles generated and formulated as described above are introduced into a region of target tissue, generally a skin region, and activated with laser-based hair removal systems as is known in the art in order to achieve effective hair removal
To achieve maximum penetration depth and concentration of plasmonic nanoparticles in the hair follicle and / or near the components of the sebaceous gland including the sebaceous duct, sebum, the epithelial bond of the sebaceous gland and / or near the prominent region including stem cells, the niche of stem cells, the epithelial lining of the prominent region and / or near the follicular bulb, an optimum particle size of 30-800 nm is constructed that contains one or more plasmonic nanoparticles. The nanoparticles that encapsulate plasmonic nanoparticles can be formulated from any number of polymers or matrices.
In some embodiments, the formulation contains a degradable or non-degradable polymer, for example, a synthetic polylactide / coglycolide copolymer, porous laurilactam / caprolactam nylon copolymer, hydroxyethylcellulose, polyelectrolyte monolayers, or alternatively, in natural hydrogels such as hyaluronic acid , jelly and others. In further embodiments, a hydrogel PLGA, PEG acrylate is included in the formulation. Preferably, a matrix component such as silica, polystyrene or polyethylene glycol is provided in the formulation to improve the stability of the particles and allow easy removal of the skin surface after application and targeting to the follicle. Other formulations include a surfactant component (for example, sodium dodecyl sulfate, sodium lauret 2-sulfate, ammonium lauryl sulfate, octech-1 / deceth-1 sodium sulfate), a lipid bilayer, a liposome or a microsome. Plasmonic nanoparticles that include nanobars, nanowires, nanospheres, nanoplates or nanoarroces can be encapsulated within a nanoparticle or matrix based on polymer or lipid or deposited on the surface of the particle. Alternatively, nanoparticles in the size range of 100-250 nm, 250-500 nm, 800-1,500 nm, or greater than 1,500 nm can be used.
Pretreatment of the skin with mechanical or chemical exfoliation is used in some embodiments to remove capillary plugs and "open" the follicle for particle delivery. In addition, the hairs can be shaved or waxed to create a vacuum in the hair follicle so that they are filled with particles. The use of physical or thermal force amplifies or accelerates the penetration of light absorbing nanoparticles and their conjugates into hair follicles, partly causing dilation of the hair follicle before the application of the nanoparticles. For example, ultrasound and other sonic forces, mechanical vibrations, hair shaft manipulation (including pulling), physical strength, thermal manipulation and other treatments are used to improve the entry of light-absorbing nanoparticles into the hair follicles. The nanoparticle formulation treatments are performed alone, in combination, sequentially or repeated 1-24 times.
An applicator is used to uniformly apply the nanoparticle composition in follicles. The applicator may be a sponge, a cloth, direct contact with a finger, a tube, a syringe, a suction device, an aerosol, an atomizer or other means known in the art. In one example, a 1 ml formulation of plasmonic nanoparticles is applied at a concentration of OD 100 with a resonance peak of 810 nm at approximately 200 cm 2 of the skin area of an adult human being with a syringe. A cloth is used to evenly distribute the solution throughout the skin area and in the hair follicles. A deep massage is applied with a mechanical vibrator for 2 minutes with or without 1 MHz ultrasound for 5 minutes, to drive the particles deep into the follicle. The particles penetrate 50-75% throughout the length of the hair at concentrations sufficient to heat the skin within a radius of 100 pm at increasing temperatures 5-20 times greater than those generated in similar volumes of adjacent skin when irradiated with a diode laser (810 nm). Acetone, ethanol or a waste removal agent can be used to remove all particles from the surface of the skin that have not been deposited in the follicle, in order to reduce or prevent non-follicular heating of the skin.
The nanoparticle formulations are tested in animal samples ex vivo, human skin samples ex vivo and in human skin in vivo, including the evaluation of: 1) penetration depth of the nanoparticles in the hair follicles; 2) particle concentration reached; 3) degree of heating reached at the concentrations of nanoparticles supplied; and 4) efficacy of photothermal destruction including temporary and permanent hair removal, 5) removal of nanoparticles after treatment. To evaluate the penetration depths of the nanoparticles, plasmonic nanoparticles are visualized with the addition of functional groups on the surface with fluorescent molecules by fluorescence microscopy after histological cutting or follicular biopsy (hair shaft removal). Alternatively, plasmonic nanoparticles are visualized directly by dark field microscopy after histological cutting or follicular biopsy. To evaluate the concentrations of nanoparticles at different depths throughout the follicle, the cut skin samples are separated by means of heat or tape extraction techniques, the samples are dissolved for bulk analysis of the metal concentration by ICP- MS (mass spectrometry with inductively coupled plasma). The macroscopic degree of heating is validated by infrared thermography of skin samples and by the evaluation of skin sections subjected to laser exposure for thermal damage markers. Finally, the efficacy of photothermal destruction at the site of nanoparticle accumulation can be measured by analyzing histological cell lesions at the target site, including the hair follicle stem, the internal root sheath, the external root sheath and the protruding region that contains the niche of stem cells, which contains the stem cells that contribute to the growth of new hair. Since the protruding region is generally located midway (~ 50% of the length) of the hair shaft, permanent hair removal is sufficiently achieved by the accumulation of plasmonic nanoparticles at this depth. In some situations, the supply of nanoparticles can also generate a heat gradient that emits below the hair shaft. Animal studies are useful for demonstrating the effectiveness of removal of non-pigmented hair by comparing heat profiles, thermal ablation of the hair shaft and thermal damage of protruding stem cells in treated hairless rodents, albino rodents and rodents. dark fur The effectiveness in live human skin is measured through hair count at 3 and 12 months of follow-up. Biopsies are taken from selected patients at 2, 4 and 6 weeks of follow-up to verify that the nanoparticles are removed from the skin without being embedded in the dermis.
Penetration of the hair follicle by fluorescently labeled nanoparticles was determined using porcine skin explants and confocal imaging. An aqueous solution of 25 mg / ml of nanoparticles coated with silicon dioxide (200 nm in diameter) with freshly thawed pig skin, after which the excess nanoparticle suspension was removed and a manual massage was performed for three minutes. The explant was sectioned and subjected to confocal images. As shown in Figure 3A, images of the explant sections were taken at angles with the hair follicles in 60 pm planes; plane 1 shows the follicle infundibulus, while plane 2 shows the distal regions of the follicle. Figure 3B shows representative confocal images demonstrating that the red nanoparticles (absorbance of 548 nm) are visible both within the superficial and deep follicles, but are not detectable in the dermal layers below the follicles. Figure 3C shows large magnification images of red nanoparticles located and retained within a deep follicle (~ 400 pm). The green color indicates tissue auto fluorescence (488 nm).
Penetration of hair follicles by plasmonic nanoparticles determined using porcine and dark-field skin images. A suspension of DO 100 plasmonic nanoparticles (200 nm in diameter) was contacted with freshly thawed pig skin, after which the excess nanoparticle suspension was removed and a manual massage was performed for three minutes. The procedure was repeated for a total of 3 applications and the surface residue was removed with several 3-5 applications alternating water and ethanol. The skin sample was cut, fixed, sectioned along the horizontal plane and subjected to dark field images. As shown in Figure 4A, skin samples were sectioned and horizontal images were taken to the hair follicle at various depths. In the images of the cutaneous section, the plasmonic nanoparticles were observed as bright blue point sources at depths up to 1.2 mm deep in the porcine follicular spaces (Figure 4B). Control samples without plasmonic nanoparticles clearly differed (Figure 4C). An ICP-MS was also performed on skin sections to evaluate nanoparticle concentrations at various depths throughout the follicle.
Penetration of hair follicles by nanoparticles in rodents without hair, albino rodents and rodents of dark fur. Swiss Webster mice with white hair (n = 3) at 8 weeks of age are anesthetized with injectable anesthetic solution of ketamine / xylazine and washed and dried the dorsal skin of the back and hair. Before administration of the formulation, three 10 cm x 10 cm areas are demarcated by a permanent marker on each mouse and subjected to hair removal with 1) electric shaver, 2) Nair hair removal reagent, or 3) application of the mixture of hot wax / rosin and peeled. Each mouse is treated by a pipette with up to 3 nanoparticle formulations, in quadruplicate with 5 pl in specific areas per demarcated area of the skin (up to 12 points per area or 36 points per mouse). Precise positions of the points are demarcated with the pen before pipetting. Duplicate treatment points on the left side are massaged into the skin for 5 minutes, while duplicate treatment points on the right side are applied without massage. Thirty minutes after application, the mice are sacrificed by asphyxiation with carbon dioxide and cervical dislocation, and the skin is carefully removed and pierced in sections along demarcations the size of the spot. Skin biopsies are fixed in 10% paraformaldehyde, embedded in paraffin and cut into 5 pm sections in a microtome in the transverse direction. Slides with mounted paraffin sections are dewaxed and stained with hematoxylin and eosin (H&E) or kept unstained for dark field microscopy. Through the use of H&E staining, light microscopy and / or dark field microscopy, images of more than 50 follicles are formed per formulation and titrations are made in the skin sections to determine the visible macroscopic accumulation of nanoparticles in the follicle, a along the capillary stem, at the site of the putative bulge stem cell niche, and to the depth of the follicle bulb. In serial histological sections, a silver staining improvement kit based on sodium thiosulfate can be used to increase the signal of plasmonic nanoparticles through precipitation of metallic silver. Phase and dark field micrographs are captured and used to record the depths of follicular penetration for each nanoparticle formulation and method of application. An ICP-MS was also performed on skin sections to evaluate nanoparticle concentrations at various depths throughout the follicle.
Evaluation of photothermal destruction at the site of nanoparticle accumulation. The treated areas of pig, human or mouse skin are irradiated with a laser coinciding with the maximum absorption wavelength of nanoparticles (for example, YAG laser at 1,064 nm for 1020 nm plasma particles) using clinical parameters (exposure of 1 s with 30-50 J / cm2 and a pulse width of 10-50 ms). To determine the microscopic photothermal damage of the target skin structures such as the hair follicle and the stem cells of the hair follicle bulge, ten days after application and irradiation, human subjects receive injections of lidocaine to numb the areas of treatment and the skin is carefully removed and perforated in sections along the demarcations of spot size. Fresh biopsies of human skin or explanted human and animal skin samples are fixed in 10% paraformaldehyde, embedded in paraffin and cut into 5 pm sections in a microtome in the transverse direction or fixed in Zamboni solution with acid 2% picric and are sectioned in a cryostat by a freezing sliding microtome. Slides with mounted paraffin sections are dewaxed and stained with hematoxylin and eosin (H&E). Histological sections are examined at various depths to detect markers of thermal damage and inflammation. Hematoxylin and eosin (H&E) are used to obtain images of the skin and microanatomy of the follicle and indicate the degeneration of the capillary stems, atrophy of the sebaceous glands and cellular vacuolization (indicating cellular damage). Tetrazolium nitro blue chloride (NBTC), a staining with lactate dehydrogenase that is lost by Thermal cell injury, is used to assess the damage of keratinocytes. Cellular damage in the follicles of skin samples that receive plasmonic nanoparticles plus laser treatment is scored and compared to those receiving laser treatment alone. Human skin areas treated in vivo are also followed up clinically for 2 weeks to 3 months after treatment with laser plasmonic nanoparticles, or during repeated treatments with laser plasmonic nanoparticles and compared with the baseline digital photograph taken before the first treatment, and with negative control treatments only with laser. Clinical observations of hair removal, as well as erythema, edema, malaise, irritation or scarring, are reviewed to determine the degree of non-specific thermal damage.
Effect of plasmonic particle coating on the specificity of the supply and photothermal heating. Preferably, a matrix component such as silica, polystyrene or polyethylene glycol is provided in the formulation to improve the stability of the particles and allow easy removal of the skin surface after application and addressing to the follicle. Acetone, ethanol or a waste eliminating agent can be used to remove all particles from the surface of the skin that have not been deposited in the follicle, in order to reduce or prevent non-follicular heating of the skin. In Figure 5, live human skin was treated with uncoated plasmonic particles compared to silica-coated plasmonic particles, before laser irradiation and compared with particleless treatment controls (laser only). Pretreatment of the skin, including shaving with a razor and microdermabrasion (15 seconds, medium fixation) to remove the capillary plugs and "open" the follicle for particle delivery, was performed on both forearms. The skin of the human forearm was irradiated with 810 nm laser pulses (30 J / cm2, 30 ms, 2 passes) only (Figure 5A), or after treatment with an 830 nm resonant formulation, plasmonic nanoparticles not coated in propylene glycol at 20% (Figure 5B). The plasmonic nanoparticle formulation was applied with a 3 minute massage and repeated 3 times, and the skin surface was cleaned with 3 alternating applications of water and ethanol before laser irradiation. Within 30 minutes after laser irradiation, nonspecific clinical burns were observed due to significant photothermal heating of uncoated residual particles on the skin surface (Figure 5B). Live human skin was also irradiated with 1,064 nm laser pulses (40 J / cm2, 55 ms, 3 passes) only (Figure 5C) or after treatment with a formulation of 1020 nm resonant silica coated plasma nanoparticles in propylene glycol at 20% (Figure 5D). The plasmonic nanoparticle formulation was applied with a 3 minute massage and repeated 3 times, and the skin surface was cleaned with 3 alternating applications of water and ethanol before laser irradiation. Within 30 minutes after laser irradiation, no evidence of skin burn or erythema was observed, since silica-coated particles could be sufficiently cleaned from the surface of the skin (Figure 5D). The enlarged photograph of the area of the skin treated with laser-coated particles shows specific photothermal damage (peripheral erythema and edema) at the site where the nanoparticles were directed, without damaging surrounding tissues or treated without particles (Figure 6).
Example 4. Use of plasmonic nanoparticles for the treatment of acne.
Methods for using the compositions described herein are provided herein for the treatment of acne vulgaris and other acne and acne-like skin conditions, but selective targeting of sebaceous follicles, particularly the sebaceous glands and / or hair follicles. Plasmonic nanoparticles generated and formulated as described above are introduced into a region of target tissue, generally a skin region, and activated with laser-based systems as is known in the art in order to achieve effective hair removal.
To achieve maximum depth of penetration and concentration of plasmonic nanoparticles in the hair follicle and / or near the components of the sebaceous gland including the sebaceous duct, sebum, epithelial junction of the sebaceous gland and / or near the region protuberant that includes stem cells, the niche of stem cells, the epithelial lining of the protuberant region and / or near the follicular bulb, an optimum particle size of 100-800 nm is constructed containing one or more plasmonic nanoparticles. The nanoparticles that encapsulate plasmonic nanoparticles can be formulated from any number of polymers or matrices. In some embodiments, the formulation contains a degradable or non-degradable polymer, for example, a synthetic polylactide / coglycolide copolymer, a porous laurilactam / caprolactam nylon copolymer, hydroxyethylcellulose, polyelectrolyte monolayers, or alternatively, in natural hydrogels such as acid hyaluronic, jelly and others. In further embodiments, a hydrogel PLGA, PEG acrylate is included in the formulation. Preferably, a matrix component such as silica, polystyrene or polyethylene glycol is provided in the formulation to improve the stability of the particles and allow for easy removal of the skin surface after application and direction to the follicle. Preferably, the formulations include surfactants (for example, sodium dodecyl sulfate, sodium lauret 2-sulfate, ammonium lauryl sulfate, octech-1 / deceth-1 sodium sulfate), components of a lipid bilayer, a liposome or a microsome. Surfactants alter the skin's epidermal barrier, emulsify sebum, improve the mixing of hydrophilic nanoparticles with hydrophobic solutions and reduce entropic barriers to deliver hydrophilic particles to hydrophobic regions of the skin (for example, between the capillary stem and the sheath or surrounding follicle). Plasmonic nanoparticles that include nanobars, nanowires, nanospheres or nanoarroces can be encapsulated within the nanoparticle or polymer matrix or deposited on the surface of the particle. Alternatively, nanoparticles in the size range of 100-250 nm, 250-500 nm, 800-1500 nm, or greater than 1,500 nm can be used.
The use of physical or thermal force amplifies or accelerates the penetration of light absorbing nanoparticles and their conjugates into hair follicles and / or sebaceous glands, in part causing dilation of the hair follicle before the application of the nanoparticles. For example, ultrasound and other sonic forces, mechanical vibrations, hair shaft manipulation (including pulling), physical strength, thermal manipulation and other treatments are used to improve the entry of light-absorbing nanoparticles into the hair follicles and / or glands sebaceous The nanoparticle formulation treatments are performed alone, in combination, sequentially or repeated 1-24 times.
Prior to the application of plasmonic nanoparticles, a pretreatment step can be performed to remove excess sebum from the surface of the skin using chemical and / or mechanical means. Pretreatment of the skin with mechanical or chemical exfoliation is used in some embodiments to remove capillary plugs and "open" the follicle for particle delivery. In addition, the hairs can be shaved or waxed to create a vacuum in the hair follicle so that they are filled with particles.
An applicator is used to uniformly apply the nanoparticle composition in the follicles. The applicator can be a sponge, a cloth, by direct contact from a finger, a tube, a syringe, a suction device, an aerosol, an atomizer or other means known in the art. In one example, a 1 ml formulation of plasmonic nanoparticles at a concentration of OD 100 with a resonance peak of 810 nm is applied to approximately 200 cm 2 of the skin of an adult human subject with a syringe. A cloth is used to distribute the solution evenly throughout the skin area and in the hair follicles. A massage of a mechanical vibrator is applied for 2 minutes with or without 1 MHz ultrasound for 5 minutes to drive the particles deep into the follicle. The particles penetrate ~ 50% over the entire length of the capillary rod in concentrations sufficient to heat the skin within a radius of 100 pm at increasing temperatures 5-20 times greater than those generated in similar volumes of adjacent skin when irradiated with a laser of diodes (810 nm). Acetone, ethanol or a waste eliminating agent can be used to remove all particles from the surface of the skin that have not been deposited in the follicle, in order to reduce or prevent non-follicular heating of the skin.
Supply of plasmonic nanoparticles to the sebaceous gland determined using human tummy tuck skin and dark field images. The human sebaceous gland exists within the pilosebaceous unit consisting of hair, hair follicle, erector hair muscle and sebaceous gland. In Figure 7A, a human skin biopsy is immunostained with antibodies against collagen IV (basement membrane marker, blue) and PGP 9.5 (nerve marker, green) to visualize the microanatomy of the representative pilosebaceous unit, including the hair follicle ( HF), the sebaceous gland (SG) and erector muscle of the hair. To administer nanoparticles to the hair follicle and the sebaceous gland, the skin was previously treated by shaving to remove extruded hair, microdermabrasion (15 seconds, medium fixation) to remove hair plugs and corneocytes and chemical hair removal to "open" the follicular micro wells for particle supply. A suspension of DO 100 plasmonic nanoparticles (200 nm in diameter), formulated in 1% sodium dodecyl sulfate (SDS) and 20% propylene glycol (PG) was contacted with skin of human abdominoplasty removed, after which it was removed the excess suspension of nanoparticles and a manual massage was performed for three minutes, followed by ultrasound (1 MHz) for 5 minutes. The procedure was repeated for a total of 3 applications and the surface residue was removed with 3-5 applications alternating water and ethanol. The skin sample was removed, fixed, sectioned along the horizontal planes and subjected to dark-field imaging. As assessed by dark-field imaging of horizontal skin sections, plasmonic nanoparticle compositions with a cosmetically acceptable carrier of 1% SDS / 20% PG administered with massage and ultrasound can be delivered at 400-600 pm deep in the human follicle and specifically in the sebaceous gland (Figure 7B).
Cosmetic formulations for supply in follicular and sebaceous glands in human skin. Preferably, the formulations include surfactants (for example, sodium dodecyl sulfate, sodium lauret 2-sulfate, ammonium lauryl sulfate, octech-1 / deceth-1 sodium sulfate), components of a lipid bilayer, a liposome or a microsome. Surfactants alter the skin's epidermal barrier and emulsify sebum to allow better mixing of hydrophilic nanoparticles in hydrophobic solutions. Moisturizers such as propylene glycol are used to help improve topical viscosity and maintain physiological pH. To demonstrate the efficacy and mechanism of the examples of cosmetic formulations for administration to human sebaceous glands, the skin was first treated by shaving to remove extruded hair, microdermabrasion (15 seconds, medium fixation) to remove hair plugs and corneocytes and chemical hair removal to "open" the follicular micro wells for particle delivery. Two separate suspensions of OD 100 of plasmonic nanoparticles (200 nm in diameter) were formulated in 1% sodium dodecyl sulfate and 20% propylene glycol (SDS / PG) or in 1% sodium lauret 2-sulfate and 20% propylene glycol . The formulations were contacted with two separate excised human tummy tuck skin samples, and a massage was performed for 3 minutes followed by ultrasound (1 MHz) for 5 min to direct particles deep into the follicles. The procedure was repeated for a total of 3 applications and the surface residue was removed with 3-5 alternate applications of water and ethanol. The skin sample was removed, fixed, sectioned along the horizontal planes and subjected to dark-field imaging to evaluate the particle supply. As assessed by dark field images of horizontal skin sections, plasmonic nanoparticle compositions with a cosmetically acceptable carrier of 1% / 20% SLES administered with massage and ultrasound can be delivered to 400-600 | jm deep in the human follicle and specifically in the sebaceous gland (Figure 8B).
Impact of massage against ultrasound on the supply of nanoparticles to human follicles and sebaceous glands. Ultrasound and other sonic forces, mechanical vibrations, hair shaft manipulation (including pull), physical strength, thermal manipulation and other treatments are used to improve the entry of light-absorbing nanoparticles into the hair follicles and / or the sebaceous glands. Mechanical massage improves follicular penetration through 'pumping' mechanisms in the hair shaft, while ultrasound improves transdermal drug administration through the temporary interruption of the lipid bilayer of the skin, bubble formation and microflow unidirectional liquid. To characterize the effects of the decoupled ultrasound massage, the skin was previously treated by shaving to remove extruded hair, microdermabrasion (15 seconds, medium fixation) to remove capillary plugs and corneocytes, and chemical hair removal to "open" the micro wells of the follicle to supply the particles. A suspension of OD 100 plasmonic nanoparticles (200 nm in diameter), formulated in 1% sodium dodecyl sulfate (20% SDS) and 20% propylene glycol (PG) was contacted with three separately removed human tummy tuck skin samples. In the three samples of human skin treated, the massage was only performed for 3 minutes, only ultrasound (1 MHz) was performed for 5 minutes, or a massage followed by ultrasound was performed to drive the particles deep into the follicles. In a fourth sample, no particles were applied to the skin. The procedure was repeated for a total of 3 applications and the surface residue was removed with 3-5 alternate applications of water and ethanol. The skin sample was removed, fixed, sectioned along horizontal planes and subjected to dark-field imaging to evaluate the particle supply. As assessed by dark-field imaging of horizontal skin sections, plasmonic nanoparticle compositions with a cosmetically acceptable carrier of 1% / 20% SLES administered through ultrasound, supply more plasmonic nanoparticles to the infundibulum versus massage , although both mechanisms facilitate the supply (Figure 9).
Additional formulations of plasmonic nanoparticles for delivery to follicles and sebaceous glands in human skin. In some embodiments, the plasmonic nanoparticles include nanobars, nanowires, nanospheres or nanoarroces, or plasmonic nanoparticles encapsulated within the nanoparticle or polymer matrix or deposited on the surface of the particle. Preferably, a matrix component such as silica, polystyrene or polyethylene glycol is provided in the formulation to improve the stability of the particles and allow easy removal of the skin surface after application and direction to the follicle. To demonstrate the formulation of forms and the supply of additional concentrations of plasmonic nanoparticles for the follicle, infundibulum and sebaceous glands, the skin was previously treated by shaving to remove extruded hair, microdermabrasion (15 seconds, medium fixation) to remove capillary plugs and corneocytes, and chemical hair removal to "open" the microwells of the follicle for particle delivery. Separately, OD 10 suspensions of silica coated nanoplates, OD 30 suspensions of polyethylene glycol coated nanobars and fluorescent silica particles were formulated in 1% sodium dodecyl sulfate and 20% propylene glycol. The formulations were contacted with three separate excised human tummy tuck skin samples, and massage was performed for 3 minutes followed by ultrasound (1 MHz) for 5 min to drive the particles deep into the follicles. The procedure was repeated for a total of 3 applications and the surface residue was removed with 3-5 alternate applications of water and ethanol. The skin sample was removed, fixed, sectioned along horizontal planes and subjected to dark-field imaging to evaluate the particle supply. As assessed by dark field images of horizontal skin sections, nanobar compositions coated with polyethylene glycol (PEG) (gold, dimension 15 x 30 nm) were observed in a cosmetically acceptable carrier, administered through ultrasound and massage, within the Follicular infundibulum 200 jm deep (Figure 10A). Compositions of plasmonic nanoparticles (silica coated nanoplates) at a lower concentration (OD 10), were evident at 400-600 pm deep in the follicle and in the sebaceous gland (arrow without padding), although at a lower concentration than comparable particles in a cosmetic carrier similar to OD 100 (Figure 10B).
Evaluation of the photothermal destruction of the sebaceous gland and target skin structures. The nanoparticle formulations are tested on samples of animal skin ex vivo, samples of human skin ex vivo and human skin in vivo as described in Example 3. The efficacy of photothermal destruction at the site of nanoparticle accumulation can be measured. measuring thermal damage to sebum cells and reduction in sebum production in treated sebaceous follicles. To evaluate photothermal destruction, human skin is first treated by shaving to remove extruded hair, microdermabrasion (15 seconds, medium fixation) to remove capillary and corneocyte plugs and chemical hair removal to "open" the follicle micro wells for Particle supply The skin is contacted with an OD 100 suspension of resonant plasmonic nanoparticles at 810 nm (200 nm in diameter), and massaged for 3 minutes followed by ultrasound (1 MHz) for 5 min to drive particles deep into the follicles . The procedure is repeated for a total of 3 applications and surface waste is removed with 3-5 alternate applications of water and ethanol. Treated human skin samples are irradiated with 810 nm laser (40 J / cm2, 30 ms, 5 pulses) and compared to human skin treated with laser only. A human skin biopsy is taken, fixed in the Zamboni solution with 2% picric acid, and sectioned on a cryostat by a freezing sliding microtome. Slides with mounted paraffin sections are dewaxed and stained with hematoxylin and eosin (H&E). The Histological sections are examined at various depths to detect markers of thermal damage and inflammation. Hematoxylin and eosin (H&E) are used to obtain images of the skin and microanatomy of the follicle and indicate the degeneration of the capillary stems, atrophy of the sebaceous glands and cellular vacuolization (indicating cellular damage). Tetrazolium nitroazul chloride (NBTC), a staining with lactate dehydrogenase that is lost by thermal cell damage, can also be used to assess the damage of keratinocytes against sebocytes. An intracellular stain, Oil-Red-O, can be used to determine the lipid and tallow oil content in the treated samples. Sebum excretion rates are measured on a skin in vivo at 1-3 months follow-up using sebum absorbent tapes to demonstrate functional change in sebum flow. The elimination and prevention of acne lesions is measured by the results reported by the patient and the acne lesion count at 1-3 months of follow-up.
Example 5. Formulation of thermoablative plasmonic nanoparticles for vascular ablation
The formulations are prepared to maximize the stability of the nanoparticles (degree of aggregation in solution), concentration of the nanoparticles and absorbance of the nanoparticles (degree of laser induced heating at different concentrations) once injected into the bloodstream. The nanoparticles are generated as in Example 1 using an appropriate solvent. The mixture comprising a plurality of nanoparticles in water is concentrated to approximately OD 100-500 at maximum absorbance and exchanged for a new solvent by liquid chromatography, a solvent exchange system, a centrifuge, precipitation or dialysis. The typical exchange solvent is 0.15 mol / L NaCl, 0.1 mol / L Na phosphate regulator (pH 7.2).
Example 6. Use of plasmonic nanoparticles for the thermoablation of a component or components of vessels and microvessels.
Compositions containing nanoparticles, typically intravascularly, are administered. After said administration of plasmonic nanoparticles, a laser adapted to the peak of plasmonic resonance of the particles (for example, 755 nm, 810 nm, or 1,064 nm) is applied to heat the nanoparticles and surrounding tissue. Pulse widths of 10-100 ns, 100 ns-1 ms, 1-10 ms, 10-100 ms, 100-1,000 ms or continuous wave irradiation are used to achieve thermal heating and heating gradients located in the vicinity of the particle or particles of 20-200 nm, 200 nm-2 pm, 2-20 pm, 20-200 pm, 200 pm-2 mm. Thermal gradients of 20 200 nm are obtained from individual particles. Thermal gradients greater than millimeters are achieved by the collective deposition of heat of many particles in veins with diameters of several hundred microns or more. Irradiation is applied from 1 pulse to many pulses in seconds to minutes. A cooling device for epidermal layers is used concomitantly with irradiation to reduce pain and prevent thermal damage in other parts. The position of the laser, the creep, the wavelength, the angle of incidence, the pattern of irradiation, are modified to achieve the irradiation of the vessels at specific depths between 0-10 mm, while avoiding the heating of the vasculature non objective. Alternatively, the laser or light is administered through a fiber optic waveguide administered through a catheter to heat the particles in larger veins.
In one embodiment, a flank of the tissue is irradiated with 2 W / cm 2, 810 nm, 1 cm in beam diameter after injection of PEG nanobars with plasmon resonance peak at 810 nm. Thermographic imaging is used to assess the surface temperature of the tissue immediately after irradiation. Evaluation of thermal damage to the component or components of vessels, microvessels or capillaries. Thirty minutes after application, the target vessels and surrounding support tissue (for example, the skin) are removed. Biopsies are fixed in 10% paraformaldehyde, embedded in paraffin and cut into 5 pm sections in a microtome in the transverse direction. Slides with mounted paraffin sections are dewaxed and stained with hematoxylin and eosin (H&E) or improved silver staining. By staining with H&E and optical microscopy, images of one or several vessels, microvessels and capillaries can be taken. Scoring is performed for visible thermal damage of vessel structures. Additionally, vessel staining (for example, staining with CD31) is performed to clearly identify vascular structures within tissue samples.
2 sheets
Sheet 1 Sheet 2
103 members in 17 offices
Priority claims15
| Document | Office | Kind | Date |
|---|---|---|---|
| 402305P | United States of America | – | |
| 40230510 | United States of America | P | |
| 40230510 | United States of America | P | |
| 422612P | United States of America | – | |
| 42261210 | United States of America | P | |
| 42261210 | United States of America | P | |
| 201161516308 | United States of America | P | |
| 201161516308 | United States of America | P | |
| 201161516308P | United States of America | – | |
| 201161516308P | – | – | – |
| 402305P | – | – | – |
| 422612P | – | – | – |
| US20100402305P | – | – | – |
| US20100422612P | – | – | – |
| US201161516308P | – | – | – |
Members103
| Document | Office | Kind | |
|---|---|---|---|
| CA2806592A1 | Canada | A1 | |
| CA3089747A1 | Canada | A1 | |
| WO2012027728A2 | World Intellectual Property Organization (WIPO) | A2 | |
| US2012059307A1 | United States of America | A1 | |
| WO2012027728A3 | World Intellectual Property Organization (WIPO) | A3 | |
| AU2011293132A1 | Australia | A1 | |
| CN103124549A | China | A | |
| EP2608762A2 | European Patent Office (EPO) | A2 | |
| JP2013537559A | Japan | A | |
| US2014005593A1 | United States of America | A1 | |
| US2014012162A1 | United States of America | A1 | |
| US2014012163A1 | United States of America | A1 | |
| US2014012183A1 | United States of America | A1 | |
| US8802154B2 | United States of America | B2 | |
| US8821940B2 | United States of America | B2 | |
| US8821941B2 | United States of America | B2 | |
| US8834933B2 | United States of America | B2 | |
| US2014316387A1 | United States of America | A1 | |
| US8895071B1 | United States of America | B1 | |
| US8906418B1 | United States of America | B1 | |
| US2014371654A1 | United States of America | A1 | |
| US2014371655A1 | United States of America | A1 | |
| US2014371656A1 | United States of America | A1 | |
| US2014371657A1 | United States of America | A1 | |
| US2014371658A1 | United States of America | A1 | |
| US2014371659A1 | United States of America | A1 | |
| US2014371660A1 | United States of America | A1 | |
| US2014371661A1 | United States of America | A1 | |
| US2014371662A1 | United States of America | A1 | |
| US2014371663A1 | United States of America | A1 | |
| US2014371664A1 | United States of America | A1 | |
| US2015005691A1 | United States of America | A1 | |
| WO2015031189A1 | World Intellectual Property Organization (WIPO) | A1 | |
| US9061056B2 | United States of America | B2 | |
| EP2608762A4 | European Patent Office (EPO) | A4 | |
| AU2011293132B2 | Australia | B2 | |
| AU2016200848A1 | Australia | A1 | |
| AU2011293132C1 | Australia | C1 | |
| JP5945540B2 | Japan | B2 | |
| US9421259B2 | United States of America | B2 | |
| US9421260B2 | United States of America | B2 | |
| US9421261B2 | United States of America | B2 | |
| US9427467B2 | United States of America | B2 | |
| US9433676B2 | United States of America | B2 | |
| US9433677B2 | United States of America | B2 | |
| US9433678B2 | United States of America | B2 | |
| US9439964B2 | United States of America | B2 | |
| US9439965B2 | United States of America | B2 | |
| US9446126B2 | United States of America | B2 | |
| JP2016188224A | Japan | A | |
| US2017000547A1 | United States of America | A1 | |
| US9572880B2 | United States of America | B2 | |
| AU2016200848B2 | Australia | B2 | |
| DE202011110916U1 | Germany | U1 | |
| AU2017202704A1 | Australia | A1 | |
| US2017151330A1 | United States of America | A1 | |
| DE202011110932U1 | Germany | U1 | |
| CN103124549B | China | B | |
| EP2608762B1 | European Patent Office (EPO) | B1 | |
| DK2608762T3 | Denmark | T3 | |
| EP3210591A1 | European Patent Office (EPO) | A1 | |
| EP3213738A1 | European Patent Office (EPO) | A1 | |
| EP3222266A1 | European Patent Office (EPO) | A1 | |
| ES2637373T3 | Spain | T3 | |
| PL2608762T3 | Poland | T3 | |
| JP6224773B2 | Japan | B2 | |
| CN107441628A | China | A | |
| EP3222266B1 | European Patent Office (EPO) | B1 | |
| JP2018065788A | Japan | A | |
| ES2670719T3 | Spain | T3 | |
| DK3222266T3 | Denmark | T3 | |
| TR2018007153T4 | Türkiye | T4 | |
| TR201807153T4 | Türkiye | T4 | |
| HK1246715A | Hong Kong, China | A | |
| HK1246715A1 | Hong Kong, China | A1 | |
| HUE038539T2 | Hungary | T2 | |
| PL3222266T3 | Poland | T3 | |
| EP3210591B1 | European Patent Office (EPO) | B1 | |
| JP6495407B2 | Japan | B2 | |
| DK3210591T3 | Denmark | T3 | |
| TR201904627T4 | Türkiye | T4 | |
| ES2717543T3This record | Spain | T3 | |
| JP2019123722A | Japan | A | |
| PL3210591T3 | Poland | T3 | |
| AU2017202704B2 | Australia | B2 | |
| BR112013007496A2 | Brazil | A2 | |
| EP3213738B1 | European Patent Office (EPO) | B1 | |
| US10537640B2 | United States of America | B2 | |
| IL224390A | Israel | A | |
| IL224390B | Israel | B | |
| DK3213738T3 | Denmark | T3 | |
| PT3213738T | Portugal | T | |
| EP2608762B2 | European Patent Office (EPO) | B2 | |
| US2020155681A1 | United States of America | A1 | |
| CN107441628B | China | B | |
| EP3673893A1 | European Patent Office (EPO) | A1 | |
| DK2608762T4 | Denmark | T4 | |
| ES2780930T3 | Spain | T3 | |
| PL2608762T5 | Poland | T5 | |
| CA2806592C | Canada | C |
Numbers
- Publication
- 2717543
- Publication, DOCDB
- 2717543
- Publication, EPODOC
- ES2717543T
- Application
- 17167546
- Application, DOCDB
- 17167546
- Application, EPODOC
- ES20170167546T
Titles2
- Spanish
- Composiciones y métodos para la termomodulación dirigida
- English
- Compositions and methods for directed thermomodulation
Classification
- CPC, 65
- A61N5/0616
- A61B18/06
- A61B18/203
- A61K8/0245
- A61K8/19
- A61K9/5115
- A61N5/062
- A61Q9/04
- A61Q19/00
- A61B2018/00476
- A61B2018/00452
- A61B2018/0047
- A61B2018/00577
- A61K9/0014
- A61K9/0009
- A61K2800/413
- A61K2800/621
- A61K2800/624
- A61K2800/81
- A61N5/0624
- A61N5/0625
- A61N7/00
- A61B2018/00458
- A61B2018/00791
- A61B2018/00809
- A61N2005/0659
- A61K8/0241
- A61B2018/068
- A61N5/0617
- A61P1/02
- A61P1/04
- A61P17/00
- A61P17/02
- A61P17/06
- A61P17/08
- A61P17/10
- A61P17/12
- A61P17/14
- A61P19/02
- A61P21/00
- A61P25/02
- A61P29/00
- A61P31/04
- A61P31/10
- A61P43/00
- A61P7/00
- A61P9/00
- A61N5/067
- A61N2007/0034
- A61K8/0283
- A61K8/29
- A61Q19/06
- A61Q19/08
- A61B17/50
- B82Y5/00
- A61K9/009
- A61B18/18
- A61K8/11
- A61K9/5123
- A61K9/5146
- A61K9/5153
- A61K41/0057
- A61K2800/622
- A61Q9/00
- A61K41/0052
- IPC, 7
- A61K8 11
- A61Q19 00
- A61K33 24
- A61K8 19
- A61K8 14
- A61K8 02
- A61N5 06